










SCLN stock quote - SciClone Pharmaceuticals, Inc. price - NASDAQ.com










































































Hot Topics:
ETFs |
Smart Portfolio |
Currencies |
Online Broker Center















Search



























Home > 
    Quotes > 
    SCLN
















SciClone Pharmaceuticals, Inc. Quote & Summary Data 


$10.95
*  
unch

unch
Get SCLN Alerts



				        *Delayed - data as of Jul. 28, 2017 11:14 ET  - 
				        
				            Find a broker to begin trading SCLN now
				        




Exchange:NASDAQ 
Industry: Health Care 
Community Rating:  
View: 
 
				    SCLN Real Time



















SCLN





 










 







Edit Symbol List




Symbol Lookup























Real Time
NLS Trade Reporting
FlashQuotes
InfoQuotes
Summary Quote
Charts
Interactive Charts
Pre-Market Charts
After Hours Charts
Revenue / EPS Summary
Company Financials
- View Competitors
- Short Interest
Company News
Press Releases
Company News
Press Releases
Sentiment
Analyst Stock Research
Stock Report
SEC Filings
- Holdings/Insider Summary
- Institutional Holdings
- Insider Form 4

Equity Options
Pre-Market Quotes
After Hours Quotes
Company Research
- StockConsultant
Stock Comparison
- Guru Analysis
Annual Report
Historical Quotes
Call Transcripts
Dividend History
Lynch Analysis
Graham Analysis
Validea Momentum Analysis
Fool Analysis
Dreman Analysis
Zweig Analysis
Fisher Analysis
OShaughnessy Analysis
ETF detail
ETF Profile
Comparison Charts



Symbol List Views
FlashQuotes
InfoQuotes
 
                    Stock Details
           
        
Summary Quote
Real-Time Quote
After Hours Quote
Pre-market Quote
Historical Quote
Option Chain
CHARTS
Basic Chart
Interactive Chart

		        
    
                COMPANY NEWS
Company Headlines
Press Releases
Market Stream
STOCK ANALYSIS
Analyst Research
Guru Analysis
Stock Report
Competitors
Stock Consultant
Stock Comparison
FUNDAMENTALS
Call Transcripts
Annual Report
Income Statement
Revenue/EPS
SEC Filings
Short Interest
Dividend History
HOLDINGS
Ownership Summary
Institutional Holdings
Insiders(SEC Form 4)






CLOSEX


Edit Symbol List



Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.








Go Now

Clear List






            Don't know the stock symbol?  Use the 
            Symbol Lookup tool.
	        
Alphabetize the sort order of my symbols
		






CLOSEX


 
Symbol Lookup











CLOSEX
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.

Access Now











 Save Stocks











































News




PriceCharts






TradeHistory





Annual Report










EarningsReport Date





Dynamic quotes: Turn Off


















                                            Best Bid/Ask
                                            


                                                    "Best Bid" is the highest price currently being offered for a block of stock.
                                                    
                                                    "Best Ask" is the lowest price currently being asked for a block of stock.
                                                




$ 10.95 / $ 11


1 Year Target





                                            Today's High /Low
                                            


                                                    "Today's High" The highest sales price the stock has achieved during the regular trading hours, the intra-day high.
                                                    
                                                    "Today's Low" The lowest sales price the stock has fallen to during the regular trading hours, the intra-day low.
                                                




$ 10.975 / $ 10.95




                                            Share Volume
                                            


                                                    "Share Volume" is the number of shares of the stock traded on the listing exchange during current trading hours. It does not include after hours volume.
                                                





97,961





                                        50 Day Avg. Daily Volume
                                        


                                                This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today's trading to the average daily volume. 
                                            




794,797




                                            Previous Close
                                            


                                                    "Previous Close" is the previous trading day's last reported trade price during official trading hours.
                                                




$ 10.95




                                            52 Week High/Low
                                            


                                                    "52 Week High" is the highest sales price the stock has achieved during the regular trading hours during the most recent 52 week period.
                                                    
                                                    "52 Week Low" is the lowest sales price the stock has fallen to during the regular trading hours during the most recent 52 week period.
                                                





                                        $ 11.10 / $ 8.55
                                    


 



                                            Market cap
                                            


	                                                “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.
                                                




$ 567,104,300 




                                            P/E Ratio
                                            


                                                    "P/E Ratio" is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm (not the same as the projected P/E ratio); it is also called the "multiple".
                                                




15.42




                                        Forward P/E(1y)
                                            


                                                        A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. 
                                                    









                                            Earnings Per Share (EPS)
                                            


	                                                    The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. 
	                                                




$ 0.71


Annualized dividend
N/A




                                            Ex Dividend Date
                                            


                                                    The data is based on historical ex-dividend data & doesn’t include upcoming values.  Visit the dividend history page to see the upcoming dividend information.
                                                




N/A


Dividend Payment Date
N/A




                                            Current Yield
                                            


                                                    Indicated yield represents annual dividends divided by current stock price. The data is based on historical ex-dividend data & doesn’t include upcoming values.  Visit the dividend history page to see the upcoming dividend information.
                                                




0 %




                                            Beta
                                            


                                                    "Beta" is a volatility measurement of a stock mutual fund or ETF versus a comparable benchmark like the S&P 500 stock index. A stock fund or ETF with a higher beta than the S&P 500 will rise or fall to a greater degree. In contrast, a stock fund or ETF with a low beta will rise or fall less.
                                                




0.35




                                            NASDAQ Official Open Price
                                            


	                                                NASDAQ Official Opening Price: This process identifies the NASDAQ-specific opening prices for NASDAQ-listed issues.
	                                                




$ 10.95




									            Date of Open Price
									            


											            "Date of Open Price" This field refers to the date the NASDAQ Official Open Price was disseminated for a given stock. It is possible that the date will not be from the current trading day; this indicates that the stock didn't trade on NASDAQ during the current trading day. The NASDAQ Official Open Price is updated only when the stock is traded on NASDAQ. 
											            




Jul. 28, 2017




                                        NASDAQ Official Close Price
                                        


                                                    "NASDAQ Official Closing Price (NOCP)" is a process for identifying the NASDAQ market-specific closing price for NASDAQ-listed issues.
                                                    




$ 10.95




                                            Date of Close Price
                                            


	                                                This field refers to the date the NOCP was disseminated for a given stock. It is possible that the date will not be from the prior day; this indicates that the stock didn't trade on NASDAQ on the prior day. The NOCP is updated only when the stock is traded on NASDAQ. 
	                                                




Jul. 27, 2017


Community Sentiment







Intraday Chart




5d


1m


6m


12m


More Charting













Company Description (as filed with the SEC)
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is a United States
("U.S.")-headquartered, China-focused, specialty pharmaceutical company with a
substantial commercial business and a product portfolio of therapies for
oncology, infectious diseases and cardiovascular disorders. We are focused on
continuing to grow our revenue and profitability. Our business and corporate
strategy is focused primarily on the People's Republic of China ("China" or
"PRC") where we have built a solid reputation and established a strong brand
through many years of experience marketing our lead product,
ZADAXIN (thymalfasin). In addition, we have an established business model with
large pharmaceutical partners to promote and sell products. We believe our sales
and marketing strengths position us to benefit from the long-term expansion of
the pharmaceutical market in China.  ... More ...  




Risk Grade

			        Where does SCLN fit in the risk graph?
				
































News for SCLN









                        Company News for June 09, 2017
                    

6/9/2017 10:23:00 AM - Zacks.com



                        Risk Arbitrage Today: Yahoo, Pandora And An M&A Fund That Has 20% In One Stock
                    

6/9/2017 4:47:00 AM - Seeking Alpha



                        Gainers & Losers Of June 8: ANAB, INO, SCLN, NLNK, JUNO...
                    

6/9/2017 1:40:00 AM - RTT News



                        BUZZ-U.S. STOCKS ON THE MOVE-Nordstrom, Alibaba, SciClone, Valeant
                    

6/8/2017 2:27:00 PM - Reuters



                        SciClone Pharmaceuticals Moves Notably Higher On Buyout
                    

6/8/2017 1:11:00 PM - RTT News




 Subscribe


                More SCLN News & Commentary



                Read SCLN Press Releases





















Consensus Recommendation


















Analyst Info


Annual EPS Est:
$


Quarterly EPS Est:



PEG Ratio:
N/A


Mean Recommendation:
3




            Data is provided by Zacks Investment Research





View All



View Summary


































CLOSEX

Edit Favorites

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.






Update

Clear List







CLOSEX
Customize your NASDAQ.com experience
Background Color Selector

Select the background color of your choice:





 Black
							





 Slate Gray
							






 Light Gray
							





 Gray Blue
							






Quote Search

Select a default target page for your quote search:



						 Real-Time

						 After Hours

						 Pre-Market
 News
					


						 Flash Quote

						 Summary Quote

						 Interactive Charts

						 Default Setting




					Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
					If, at any time, you are interested in reverting to our default settings, please select Default Setting above.
					
					If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com.
				





CLOSEX
Please confirm your selection:

					You have selected to change your default setting for the Quote Search. This will now be your default target page;
					unless you change your configuration again, or you delete your
					cookies. Are you sure you want to change your settings?


YES
NO













CLOSEX


Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.





CLOSEX









































SciClone Pharmaceuticals, Inc.: NASDAQ:SCLN quotes & news - Google FinanceCookies help us deliver our services. By using our services, you agree to our use of cookiesLearn moreGot itMy AccountSearchMapsYouTubePlayNewsGmailDriveCalendarGoogle+TranslatePhotosMoreShoppingWalletFinanceDocsBooksBloggerContactsHangoutsKeepEven more from GoogleSign inHidden fieldsSearch FinanceAdobe Flash Player is required for interactive charts. AllowFinanceSciClone Pharmaceuticals, Inc.(NASDAQ:SCLN)Add to portfolioCompanySummaryNewsRelated companiesHistorical pricesFinancialsMarketsNewsPortfoliosStock screenerGoogle Domestic TrendsRecent Quotes (30 days)You have no recent quoteschg | %




SciClone Pharmaceuticals, Inc.  (Public, NASDAQ:SCLN)  
Watch this stock
 




















10.95


0.00
(0.00%)





Real-time:
 

11:26AM EDT



NASDAQ
real-time data -
Disclaimer

Currency in USD







Range

10.95 - 10.98



52 week

8.55 - 11.10



Open

10.95



Vol / Avg.

97,961.00/721,636.00



Mkt cap

566.47M



P/E

14.58



Div/yield

    -



EPS

0.75



Shares

51.73M



Beta

1.71



Inst. own

74%
































News





Relevance



Date











All news for SciClone Pharmaceuticals, Inc. »

Subscribe






Advertisement




Events




Add SCLN to my calendars





Aug 7, 2017
Q2 2017 SciClone Pharmaceuticals Inc Earnings Release (Estimated)
- 9:30AM EDT -






Jun 9, 2017
SciClone Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)



Jun 8, 2017
SciClone Pharmaceuticals Inc Annual Shareholders Meeting



May 10, 2017
Q1 2017 SciClone Pharmaceuticals Inc Earnings Call -






May 10, 2017
Q1 2017 SciClone Pharmaceuticals Inc Earnings Release





More events from DailyFinance » 
  



Key stats and ratios




Q1 (Mar '17)
2016


Net profit margin
34.03%
19.19%

Operating margin
33.19%
20.76%

EBITD margin
-
21.37%

Return on average assets
23.64%
13.40%

Return on average equity
26.09%
15.56%

Employees
570
-

CDP Score
-

-


Screen stocks with similar metrics »

Address
950 Tower Ln Ste 900FOSTER CITY, CA 94404-2125United States
- Map+1-650-3583456 (Phone)+1-650-3583469 (Fax)

Website links


http://www.sciclone.com/



External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters















Settings |
Technicals |



Link to this view



Volume delayed by 15 mins.Prices are not from all markets.

Sources include SIX.




















Advertisement







Related companies





Show:


Most Recent Quarter


Most Recent Annual




Add or remove columns
Save changes
Cancel







Sector: Healthcare > Industry: Pharmaceuticals - NEC

More from FactSet »










Description




SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.


More from Reuters »








Officers and directors





Jon S Saxe

Independent Chairman of the Board





Age: 79

Bio & Compensation
 - Reuters

Friedhelm Blobel Ph.D.

President, Chief Executive Officer, Director





Age: 66

Bio & Compensation
 - Reuters

Wilson W. Cheung

Chief Financial Officer, Senior Vice President - Finance, Secretary





Age: 46

Bio & Compensation
 - Reuters

Hong Zhao

Chief Executive Officer - China Operations





Age: 51

Bio & Compensation
 - Reuters

Raymond Anthony Low CPA

Vice President - Finance, Controller





Age: 58

Bio & Compensation
 - Reuters

Lan Xie CPA

Vice President - Finance, China Chief Financial Officer





Age: 42

Bio & Compensation
 - Reuters

Nancy T. Chang Ph.D.

Independent Director





Age: 65

Bio & Compensation
 - Reuters

Richard James Hawkins

Independent Director





Age: 67

Bio & Compensation
 - Reuters

Anthony Gregg Lapointe

Independent Director





Age: 57

Bio & Compensation
 - Reuters

Simon Li

Independent Director





Age: 65

Bio & Compensation
 - Reuters



Full list on Reuters »








Google Finance Beta available in: Hong Kong - Canada - U.S. - China - U.K.Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.To see all exchange delays, please  see disclaimer.©2017 Google - Google Home - Blog - Help - Report a Problem - Privacy Policy - Terms of Service








	SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)























































 
 







Contact Us | Site Map   中国  | English



































NEWS + EVENTS



June 8, 2017 - SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital
May 10, 2017 - SciClone Reports First Quarter 2017 Financial Results
May 4, 2017 - SciClone Pharmaceuticals To Report First Quarter 2017 Financial Results On May 10, 2017














Login
© 2017 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer.
Terms of Use | Notes Regarding Forward Looking Statements
年赛生制药公司保留所有权利。请阅读我们的免责声明。 使用条款 | 注意有关前瞻性陈述














	SciClone Pharmaceuticals, Inc. Marketed and Development Products





















































 







Contact Us | Site Map   中国  | English











Product Portfolio
















 
THERAPEUTIC AREA
PRODUCT
STATUS
PARTNER


MARKETED PORTFOLIO
“…it's not enough anymore just to have generics. That might work for the immediate future…but beyond that you need to have differentiated products if you want to remain or become a player in the pharmaceutical market.”
-Dr. Blobel on evolving China pharma market,
              BioWorld Today, November 13, 2013

HBV, HCV, Cancer, Immune System Enhancer; Sepsis
ZADAXIN
Marketed since 1996
SciClone Proprietary



Oncology


Holoxan
Mesna
Endoxan
Methotrexate
Farlutal
Estracyt
DC Bead


Marketed
Marketed
Marketed
Marketed
Marketed
Marketed
Marketed


Baxter
Baxter
Baxter
Pfizer
Pfizer
Pfizer
BTG




SciClone is building a portfolio of high-quality, differentiated branded products with established pedigrees as safe and effective treatments in major therapeutic areas relevant to the Chinese patient population such as oncology, cardiovascular disease and infectious disease. Each of these products exemplifies the attributes that are well-suited for the evolving China pharma market.
Our marketed product portfolio is led by our proprietary flagship product, the immunostimulatory agent ZADAXIN®, newly launched novel oncology product DC Bead® and a line-up of standard-of-care oncology products.



 
THERAPEUTIC AREA
PRODUCT
STATUS
PARTNER


DEVELOPMENT PORTFOLIO

Oncology
 


SGX942
ABTL0812
PT-112


Phase 2
Early Clinical
Phase 1


Soligenix, Inc.
Ability Pharma
Phosplatin Therapeutics



Cardiovascular

Angiomax
Neucardin
Cleviprex


NDA in review
Phase 3
CTA application filed


The Medicines Co.
Zensun
The Medicines Co.



Anti-Infective

Loramyc
VIBATIV


NDA in preparation
CTA application planning


Onxeo
Theravance Biopharma




Our development portfolio includes potential therapeutic class leaders approved in Western markets, such as the cardiovascular drugs ANGIOMAX® and Neucardin™, and the antibiotic VIBATIV®, which could move through the regulatory process as mid-term market opportunities.
We have built this attractive portfolio through targeted and successful partnering with leading pharmaceutical and biotechnology companies, including multinational corporations and innovative biopharma companies in the US, Europe, and China.































Login
© 2017 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer.
Terms of Use | Notes Regarding Forward Looking Statements
年赛生制药公司保留所有权利。请阅读我们的免责声明。 使用条款 | 注意有关前瞻性陈述










SciClone Pharmaceuticals, Inc.: Private Company Information - Bloomberg









































  





















































































July 28, 2017 11:29 AM ET
Pharmaceuticals

Company Overview of SciClone Pharmaceuticals, Inc.



Snapshot People




Company Overview
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhancer. In addition, the company focuses on developing ZADAXIN for the treatment of sepsis. SciClone Pharmaceuticals, Inc. markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets and distributes products, such as DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, ...
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhancer. In addition, the company focuses on developing ZADAXIN for the treatment of sepsis. SciClone Pharmaceuticals, Inc. markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets and distributes products, such as DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, Angiomax, and Cleviprex. The company has a strategic partnership with The Medicines Company to promote Angiomax (bivalirudin) and Cleviprex (clevidipine). SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.
Detailed Description


950 Tower LaneSuite 900Foster City, CA 94404United StatesFounded in 1989570 Employees



Phone: 650-358-3456

Fax: 650-358-3469

www.sciclone.com







Key Executives for SciClone Pharmaceuticals, Inc.




Dr. Friedhelm Blobel Ph.D.


      	Chief Executive Officer, President and Executive Director
      


Age: 68
        

Total Annual Compensation: $650.0K








Mr. Wilson W. Cheung


      	Chief Financial Officer and Senior Vice President of Finance
      


Age: 48
        

Total Annual Compensation: $586.8K








Mr. Hong Zhao


      	Chief Executive Officer of China Operations
      


Age: 54
        

Total Annual Compensation: $702.4K








Ms. Lan Xie


      	Vice President of Finance and Chief Financial Officer of China Operations
      


Age: 44
        

Total Annual Compensation: $381.6K





Compensation as of Fiscal Year 2016. 

SciClone Pharmaceuticals, Inc. Key Developments

SciClone Pharmaceuticals, Inc. Announces Election of Directors
Jun 9 17
SciClone Pharmaceuticals, Inc. elected Jon S. Saxe, Friedhelm Blobel, Ph.D. and Simon Li as directors, at the annual meeting of stockholders of the company held on June 8, 2017.


SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017
May 10 17
SciClone Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. The company's revenues in the first quarter of 2017 were $42.9 million, a $6.4 million or 18% increase, compared to $36.5 million for the same period in 2016. On a GAAP basis, the company reported net income in the first quarter of 2017 of $14.6 million, or $0.28 and $0.28 per share on a basic and diluted basis, respectively, compared to net income of approximately $7.9 million, or $0.16 and $0.15 per share on a basic and diluted basis, respectively, for the same period in 2016. The company's non-GAAP net income in the first quarter of 2017 was $16.6 million, or $0.32 and $0.31 per share on a basic and diluted basis, respectively, compared with non-GAAP net income of $9.7 million, or $0.20 and $0.19 per share on a basic and diluted basis, respectively, for the same period of the prior year. Both GAAP and non-GAAP net income were favorably impacted by the additional revenue recognition for ZADAXIN fourth quarter sales and a Chinese government subsidy in the first quarter of 2017. Income from operations was $14.2 million compared with $9.4 million a year ago. Income before provision for income tax was $15.6 million compared with $9.8 million a year ago.


SciClone Pharmaceuticals, Inc. Announces Changes in Bylaws
May 9 17
On May 4, 2017, the Board of Directors of SciClone Pharmaceuticals, Inc. approved amendments to the Company's Amended and Restated Bylaws to a add a new provision to the company's Bylaws that designates the state and federal courts located within the State of Delaware as the sole and exclusive forum for certain legal actions, unless the Company consents in writing to the selection of an alternative forum. The Bylaws became effective immediately.


Similar Private Companies By Industry



Company Name
Region



 1st Order Pharmaceuticals, Inc. United States 21st Century Animal Health United States 3 Buds' Organics LLC United States 4P Therapeutics LLC United States 60° Pharmaceuticals, LLC United States




Recent Private Companies Transactions



TypeDate
Target





Merger/Acquisition

			      November 14, 2016
			    
--



Private Placement

			      September 9, 2016
			    
Soligenix, Inc.





Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States The Advertising Council, Inc. United States Bertelsmann AG Europe Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact SciClone Pharmaceuticals, Inc., please visit www.sciclone.com.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























SciClone Pharmaceuticals, Inc. > Investors



















































   








 Contact Us | Site Map   中国  | English 


















Investors



























	SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone’s proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as an immune system enhancer, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Through its promotion business with pharmaceutical partners, SciClone also markets multiple branded products in China which are therapeutically differentiated. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. 

SciClone Corporate Presentation, June 2017










NASDAQ: SCLN


$ 10.95

        		0.00 (0.00%)



        	Day High: 10.98
            
            Day Low:  10.95
            
        	Volume:    97,761
		

        	11:12 AM ET  Jul 28, 2017
        

Delayed ~20 min., by eSignal.




3 mo.
6 mo.
1 yr.
















May 10/ 2017 4:30 PM ET
                        Q1 2017 SciClone Pharmaceuticals, Inc. Earnings













Press Room
Jun 8, 2017
SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital
May 10, 2017
SciClone Reports First Quarter 2017 Financial Results
View all press room »


Calendar of Events
May 10, 2017 at 4:30 PM ET
Q1 2017 SciClone Pharmaceuticals, Inc. Earnings
Apr 4, 2017 at 5:00 PM ET
16th Annual Needham Healthcare Conference
View all calendar of events »







































 
Email Alerts
Email Alerts
 
 
Snapshot
Snapshot
 

RSS
RSS
 
 
Print
Print
 
 
Email
Email
 

Search
Search






















 © 2017 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer. Terms of Use | Notes Regarding Forward Looking Statements 
年赛生制药公司保留所有权利。请阅读我们的免责声明。 使用条款 | 注意有关前瞻性陈述











 


Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft













    SCLN Key Statistics - SciClone Pharmaceuticals Inc. Financial Ratios - MarketWatch




































Bulletin






Investor Alert







London Markets Close in:



Currencies
Futures
Metals Stocks


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































SciClone Pharmaceuticals Inc.

                  NASDAQ: SCLN
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

SciClone Pharmaceuticals Inc.



Market open
 --Real time quotes
Jul 28, 2017, 11:26 a.m.


SCLN

/quotes/zigman/77751/composite


$
10.95




Change

0.00
0.00%

Volume
Volume 99,293
Real time quotes








/quotes/zigman/77751/composite
Previous close

$
			10.95
		


$
				10.95
			
Change

0.00
0.00%





Day low
Day high
$10.95
$10.98










52 week low
52 week high

            $8.55
        

            $11.10
        

















			Company Description 


			SciClone Pharmaceuticals, Inc. is a pharmaceutical company. It engages in the development of therapeutics treatment for oncology, infectious diseases and cardiovascular disorders. Its product includes ZADAXIN, Holoxan, Mesna, Endoxan, Farlutal, Methotrexate. Estracyt, DC Bead, Angiomax, Neucardin, C...
		


                SciClone Pharmaceuticals, Inc. is a pharmaceutical company. It engages in the development of therapeutics treatment for oncology, infectious diseases and cardiovascular disorders. Its product includes ZADAXIN, Holoxan, Mesna, Endoxan, Farlutal, Methotrexate. Estracyt, DC Bead, Angiomax, Neucardin, Cleviprex, Loramyc, and VIBATIV. The company was founded in 1990 and is headquartered in Foster City, CA.
            




Valuation

P/E Current
18.88


P/E Ratio (with extraordinary items)
15.49


P/E Ratio (without extraordinary items)
18.62


Price to Sales Ratio
3.55


Price to Book Ratio
2.57


Price to Cash Flow Ratio
16.44


Enterprise Value to EBITDA
12.72


Enterprise Value to Sales
2.61

Efficiency

Revenue/Employee
280,870.00


Income Per Employee
53,911.00


Receivables Turnover
3.96


Total Asset Turnover
0.70

Liquidity

Current Ratio
7.40


Quick Ratio
6.78


Cash Ratio
5.08



Profitability

Gross Margin
85.70


Operating Margin
20.76


Pretax Margin
21.32


Net Margin
19.19


Return on Assets
13.40


Return on Equity
15.56


Return on Total Capital
15.56


Return on Invested Capital
15.56

Capital Structure




      Officers and Executives
    



Name
Age
Officer Since
Title





Dr. Friedhelm  Blobel 
67
2006
President, Chief Executive Officer & Director



Mr. Wai-Shun  Cheung 
48
2013
Chief Financial Officer & Senior VP-Finance



Mr. Carey  Chern 
50
2016
Secretary & Chief Compliance Officer



Ms. Lan  Xie 
44
2012
CFO-China Operations & Vice President-Finance



Mr. Hong  Zhao 
52
2013
Chief Executive Officer-China Operations





Insider Actions


 – Purchase

 – Sale
1
 – Number of Transactions











{"OrganizationDocuments":[{"Documents":[{"document":[{"reportDateGroup":[{"reportDate":"2011-06-09","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-05-17","tradeTypeGroup":[{"numTransactions":"3","tradeType":"D"},{"numTransactions":"1","tradeType":"A"}]},{"reportDate":"2011-05-16","tradeTypeGroup":[{"numTransactions":"2","tradeType":"D"},{"numTransactions":"8","tradeType":"A"}]},{"reportDate":"2011-05-13","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-12","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-11","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-02","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-03-10","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-02-17","tradeTypeGroup":[{"numTransactions":"4","tradeType":"D"},{"numTransactions":"2","tradeType":"A"}]},{"reportDate":"2011-02-15","tradeTypeGroup":[{"numTransactions":"8","tradeType":"A"},{"numTransactions":"1","tradeType":"D"}]}]}]}]}]}


Date
Name
Shares
Transaction
Value





06/30/2017

Friedhelm Blobel 
President & CEO; Director

7,390


 
Disposition at $11 per share.


81,290


06/30/2017

Friedhelm Blobel 
President & CEO; Director

27,654


 
Disposition at $11 per share.


304,194


06/30/2017

Friedhelm Blobel 
President & CEO; Director

7,390


 
Derivative/Non-derivative trans. at $5.13 per share.


37,910


06/30/2017

Friedhelm Blobel 
President & CEO; Director

27,654


 
Derivative/Non-derivative trans. at $3.55 per share.


98,171


06/20/2017

Friedhelm Blobel 
President & CEO; Director

40,000


 
Disposition at $10.91 per share.


436,400


06/20/2017

Friedhelm Blobel 
President & CEO; Director

30,000


 
Disposition at $10.9 per share.


327,000


06/20/2017

Friedhelm Blobel 
President & CEO; Director

40,000


 
Derivative/Non-derivative trans. at $3.55 per share.


142,000


06/20/2017

Friedhelm Blobel 
President & CEO; Director

30,000


 
Derivative/Non-derivative trans. at $3.55 per share.


106,500


06/12/2017

Friedhelm Blobel 
President & CEO; Director

26,090


 
Derivative/Non-derivative trans. at $10.75 per share.


280,467


06/12/2017

Wai-Shun Cheung 
CFO & Senior VP, Finance

25,000


 
Disposition at $10.75 per share.


268,750


06/12/2017

Wai-Shun Cheung 
CFO & Senior VP, Finance

3,000


 
Disposition at $10.75 per share.


32,250


06/12/2017

Wai-Shun Cheung 
CFO & Senior VP, Finance

12,500


 
Disposition at $10.75 per share.


134,375


06/12/2017

Lan Xie 
VP Finance, China CFO

1,000


 
Disposition at $10.75 per share.


10,750


06/12/2017

Hong Zhao 
CEO, China Operations

25,000


 
Disposition at $10.75 per share.


268,750


06/12/2017

Hong Zhao 
CEO, China Operations

12,500


 
Disposition at $10.75 per share.


134,375


06/12/2017

Hong Zhao 
CEO, China Operations

3,000


 
Disposition at $10.75 per share.


32,250


06/12/2017

Friedhelm Blobel 
President & CEO; Director

50,000


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Friedhelm Blobel 
President & CEO; Director

5,000


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Raymond Anthony Low 
VP, Finance & Controller

1,250


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Wai-Shun Cheung 
CFO & Senior VP, Finance

25,000


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Wai-Shun Cheung 
CFO & Senior VP, Finance

3,000


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Wai-Shun Cheung 
CFO & Senior VP, Finance

12,500


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Lan Xie 
VP Finance, China CFO

1,000


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Hong Zhao 
CEO, China Operations

3,000


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Hong Zhao 
CEO, China Operations

25,000


 
Derivative/Non-derivative trans. at $0 per share.


0


06/12/2017

Hong Zhao 
CEO, China Operations

12,500


 
Derivative/Non-derivative trans. at $0 per share.


0


06/08/2017

Friedhelm Blobel 
President & CEO; Director

19,956


 
Disposition at $11 per share.


219,516


06/08/2017

Friedhelm Blobel 
President & CEO; Director

19,956


 
Derivative/Non-derivative trans. at $3.55 per share.


70,843


06/07/2017

Friedhelm Blobel 
President & CEO; Director

19,700


 
Disposition at $10.03 per share.


197,591


06/07/2017

Friedhelm Blobel 
President & CEO; Director

19,700


 
Derivative/Non-derivative trans. at $3.55 per share.


69,935


06/06/2017

Friedhelm Blobel 
President & CEO; Director

5,500


 
Disposition at $10 per share.


55,000


06/06/2017

Friedhelm Blobel 
President & CEO; Director

5,500


 
Derivative/Non-derivative trans. at $3.55 per share.


19,525


06/02/2017

Friedhelm Blobel 
President & CEO; Director

4,800


 
Disposition at $10 per share.


48,000


06/02/2017

Friedhelm Blobel 
President & CEO; Director

4,800


 
Derivative/Non-derivative trans. at $3.55 per share.


17,040


05/24/2017

Friedhelm Blobel 
President & CEO; Director

6,298


 
Disposition at $9.36 per share.


58,949


05/24/2017

Friedhelm Blobel 
President & CEO; Director

6,298


 
Derivative/Non-derivative trans. at $3.55 per share.


22,357


05/23/2017

Friedhelm Blobel 
President & CEO; Director

15,166


 
Disposition at $9.31 per share.


141,195


05/23/2017

Friedhelm Blobel 
President & CEO; Director

15,166


 
Derivative/Non-derivative trans. at $3.55 per share.


53,839


05/22/2017

Friedhelm Blobel 
President & CEO; Director

18,536


 
Disposition at $9.44 per share.


174,979


05/22/2017

Friedhelm Blobel 
President & CEO; Director

18,536


 
Derivative/Non-derivative trans. at $3.55 per share.


65,802








/news/latest/company/us/scln

      MarketWatch News on SCLN
    




 SciClone Pharmaceuticals' stock tumbles after ending discussions with acquirers
9:21 a.m. July 19, 2016
 - Tomi Kilgore




 Nasdaq nails the 200-day average, lifts from support
11:19 a.m. June 15, 2016
 - Michael Ashbaugh




 SciClone to restate results due to China errors
7:07 p.m. Feb. 24, 2013
 - MarketWatch.com




 Monday’s biggest gaining and declining stocks
4:12 p.m. Aug. 13, 2012
 - MarketWatch




 Updates, advisories and surprises
6:01 p.m. Aug. 9, 2012
 - MarketWatch




 SciClone jumps 17% in wake of earnings report
2:09 p.m. Aug. 9, 2012
 - Val Brickates Kennedy




 SciClone up 12% after earnings
11:10 a.m. Aug. 9, 2012
 - Val Brickates Kennedy




 Updates, advisories and surprises
4:31 p.m. March 14, 2012
 - MarketWatch




 SciClone soars 24% on earnings report
2:05 p.m. March 14, 2012
 - Val Brickates Kennedy




 Stocks to watch Tuesday: Armstrong World, Copart
6:40 a.m. March 13, 2012
 - MarketWatch




 SciClone Pharma to buy back up to $20M stock
8:23 a.m. Oct. 4, 2011
 - MarketWatch.com




 Japanese drug stocks rebound
3:36 p.m. March 17, 2011
 - Val Brickates Kennedy




 Thursday’s biggest gainers and decliners
5:31 p.m. Dec. 16, 2010
 - Kate Gibson




 Motorola among active after-hours stocks
6:12 p.m. Dec. 15, 2010
 - Rex Crum




 Tuesday's biggest gaining and declining stocks
4:40 p.m. Aug. 10, 2010
 - MarketWatch




 SciClone, Synta lead decliners
3:34 p.m. Aug. 10, 2010
 - Val Brickates Kennedy




 SciClone tumbles on SEC probe
9:21 a.m. Aug. 10, 2010
 - Val Brickates Kennedy




 Friday's biggest gaining and declining stocks
2:48 p.m. April 9, 2010
 - Kate Gibson




 SciClone, Gentium, Rexahn in spotlight
1:08 p.m. April 9, 2010
 - Val Brickates Kennedy




 SciClone rallies on upgrade; drug indices diverge
9:49 a.m. April 9, 2010
 - Val Brickates Kennedy


Loading more headlines...







/news/nonmarketwatch/company/us/scln

      Other News on SCLN
    





Company News for June 09, 2017

10:23 a.m. June 9, 2017
 - Zacks.com





SciClone Pharma to be acquired by Chinese consortium for $605M; shares up 7% premarket

6:58 a.m. June 8, 2017
 - Seeking Alpha





Stonepine Capital Management, LLC Buys Viveve Medical Inc, Avadel Pharmaceuticals PLC, ...

6:38 p.m. May 15, 2017
 - GuruFocus.com





SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q1 2017 Results - Earnings Call Transcript

10:43 p.m. May 10, 2017
 - Seeking Alpha




 10-Q: SCICLONE PHARMACEUTICALS INC
4:43 p.m. May 10, 2017
 - Edgar Online -  (EDG = 10Q, 10K)





Stonepine Capital Management, LLC Buys Recro Pharma, SciClone Pharmaceuticals, Novelion ...

6:38 p.m. March 21, 2017
 - GuruFocus.com





SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Earnings Call Transcript

2:39 p.m. March 6, 2017
 - Seeking Alpha





SciClone Pharmaceuticals: Beyond The Death Of A Sales Process

3:56 p.m. Feb. 2, 2017
 - Seeking Alpha





Adds and drops from the Nasdaq Biotech Index

1:35 p.m. Dec. 13, 2016
 - Seeking Alpha





Week In Review: Week's China Life Science Deals Total $795 Million

10:29 a.m. Nov. 20, 2016
 - Seeking Alpha





SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2016 Results - Earnings Call Transcript

7:36 a.m. Nov. 11, 2016
 - Seeking Alpha




 10-Q: SCICLONE PHARMACEUTICALS INC
5:36 p.m. Nov. 9, 2016
 - Edgar Online -  (EDG = 10Q, 10K)





Valuation Dashboard: Healthcare - Update

9:00 a.m. Nov. 9, 2016
 - Seeking Alpha





Week In Review: Big Week For Cross-Border Life Science Deals

7:07 a.m. Oct. 2, 2016
 - Seeking Alpha





SciClone advances clinical pipeline for China Pharma market

8:19 a.m. Sept. 26, 2016
 - Seeking Alpha





Week In Review: China's Luxin Invests In $215 Million Funding For Intarcia's Long-Term Diabetes Device

5:37 a.m. Sept. 18, 2016
 - Seeking Alpha





Soligenix and SciClone ink dusquetide development deal in Asia

1:04 p.m. Sept. 12, 2016
 - Seeking Alpha





Valuation Dashboard: Healthcare - Update

12:08 p.m. Sept. 8, 2016
 - Seeking Alpha





Sciclone Pharmaceuticals Inc (SCLN) President & CEO Friedhelm Blobel Sold $5 million of Stocks

10:15 p.m. Aug. 18, 2016
 - GuruFocus.com





Are High Composite Ratings An Automatic 'Buy' Signal? No. Here's Why

11:41 a.m. Aug. 10, 2016
 - Investors Business Daily


Loading more headlines...












At a Glance

SciClone Pharmaceuticals, Inc.
950 Tower Lane
Suite 900

Foster City, California 94404-2125




Phone
1 6503583456


Industry
Pharmaceuticals


Sector
Health Care/Life Sciences


Fiscal Year-end
12/2017


View SEC Filings




Revenue
$160.10M


Net Income
$30.73M


2016 Sales Growth 
1.8%


Employees

        570.00


Annual Report for SCLN











/news/pressrelease/company/us/scln

      Press Releases on SCLN
    




 Lifshitz&Miller LLP Announces Investigation of ARI Network Services, Inc., DuPont Fabros Technology, Inc., Nexvet Biopharma Public Limited Company, PAREXEL International Corporation, Rice Energy Inc. and SciClone Pharmaceuticals, Inc.
3:55 p.m. July 3, 2017
 - PR Newswire - PRF




 Daily Technical Summary Reports on Drug Makers Stocks -- Apricus Biosciences, DURECT, Sucampo Pharma, and SciClone Pharma
6:25 a.m. June 28, 2017
 - PR Newswire - PRF




 SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the 
      Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors 
      to Contact the Firm for Additional Information
5:52 p.m. June 13, 2017
 - BusinessWire - BZX




 SCICLONE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, 
      P.A. Announces Investigation of Buyout
2:05 p.m. June 13, 2017
 - BusinessWire - BZX




 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation 
      Concerning Whether the Sale of SciClone Pharmaceuticals Inc. to a 
      Consortium is Fair to Shareholders – SCLN
10:24 a.m. June 13, 2017
 - BusinessWire - BZX




 WeissLaw LLP: The Proposed Acquisition of SciClone Pharmaceuticals Inc. May Not Be In the Best Interest of SCLN Shareholders
5:37 p.m. June 12, 2017
 - PR Newswire - PRF




 SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital
6:00 a.m. June 8, 2017
 - PR Newswire - PRF




 What Biotech Offers a Better Risk/Reward Profile than Soligenix (SNGX)? In Our View, None
9:02 a.m. June 7, 2017
 - ACCESSWIRE




 SciClone Reports First Quarter 2017 Financial Results
4:05 p.m. May 10, 2017
 - PR Newswire - PRF




 SciClone Pharmaceuticals To Report First Quarter 2017 Financial Results On May 10, 2017
6:00 a.m. May 4, 2017
 - PR Newswire - PRF




 SciClone To Present At Needham Healthcare Conference On April 4, 2017
6:00 a.m. March 27, 2017
 - PR Newswire - PRF




 How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma
7:25 a.m. March 20, 2017
 - PR Newswire - PRF




 SciClone Reports 2016 Financial Results And 2017 Outlook
7:00 a.m. March 6, 2017
 - PR Newswire - PRF




 SciClone Pharmaceuticals Partnering Deals and Alliances 2010 to 2017
9:35 p.m. Feb. 28, 2017
 - PR Newswire - PRF




 SciClone Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Financial Results On March 6, 2017
7:00 a.m. Feb. 21, 2017
 - PR Newswire - PRF




 Healthcare Stocks Under Scanner -- Aerie Pharma, GW Pharma, Retrophin, and SciClone Pharma
8:50 a.m. Feb. 9, 2017
 - PR Newswire - PRF




 SciClone To Present At BIO CEO & Investor Conference On February 13, 2017
7:00 a.m. Feb. 1, 2017
 - PR Newswire - PRF




 Research Reports Initiation on Drug Makers Stocks -- Amphastar Pharma, United Therapeutics, MEI Pharma, and SciClone Pharma
8:45 a.m. Nov. 15, 2016
 - PR Newswire - PRF




 SciClone Confirms Receipt Of Unsolicited Proposal From GL Capital And ABG Management
5:05 p.m. Nov. 14, 2016
 - PR Newswire - PRF




 SciClone Reports Third Quarter 2016 Financial Results
5:05 p.m. Nov. 9, 2016
 - PR Newswire - PRF


Loading more headlines...









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




11:29 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:27aWhat is an ICO?
11:22aOne way you’re paying credit-card fees, even if you don’t have a card
11:18aStock market edges lower, on track for weekly losses 
11:18aOil sets sights on biggest weekly gain of the year
11:16aUPDATE: Invisalign maker Align stocks surge 8% after earnings blow past estimates
11:12aAirbus to sell plant holdings to Motorola
11:11aAmerican Airlines profit falls, unit revenue gains
11:11aChevron swings to profit as charges shrink
11:11aSears Canada's biggest shareholders call off bid
11:10aRedfin's stock debuts 30% above its IPO price
11:10aTime for GOP to face reality: Everybody is going to have health insurance
11:09aBP earnings: What to expect
11:09aExxon, Chevron post strong profits 
11:08aChina penalizes nine banks for forex violations
11:06aRedfin's stock opens at $19.56, or 30% above $15 IPO price
11:03aEurope’s refugee crisis won’t be solved in a distant court
11:01aWhat Trump could do to make Obamacare ‘implode’
10:58aFoxconn’s history of broken promises casts a shadow on Wisconsin news
10:56aHere’s something that can improve your memory — and help you sleep
10:56a$1 million or $5,000 a month: which would you choose?
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,777.91

-18.64
-0.09%





nasdaq

/quotes/zigman/12633936/realtime
6,360.53

-21.66
-0.34%





s&p 500

/quotes/zigman/3870025/realtime
2,467.50

-7.92
-0.32%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































SciClone Pharmaceuticals, Inc. > Press Room



















































   








 Contact Us | Site Map   中国  | English 


















Press Room

























Year:

All Years
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999


Sort By:

Date Descending
Date Ascending

Update

 

Press Room








 
Date 
Title
View





Jun 8, 2017
SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital

FOSTER CITY, Calif., June 8, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) (the "Company" or "SciClone") and a consortium consisting of entities affiliated with GL Capital Management GP Limited ("GL Capital"), Bank of China Group Investment Limited ("BOCGI"), CDH Investments, Ascendent Capital Partners and Boying (collectively,...





PDF





May 10, 2017
SciClone Reports First Quarter 2017 Financial Results

FOSTER CITY, Calif., May 10, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2017.





Revenues: In the first quarter 2017, SciClone reported revenues of $42.9 million, compared to $36.5 million for the same period in 2016.

GAAP Diluted EPS: In the first q...





PDF





May 4, 2017
SciClone Pharmaceuticals To Report First Quarter 2017 Financial Results On May 10, 2017

FOSTER CITY, Calif., May 4, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2017 on Wednesday, May 10, 2017. SciClone will host a conference call and webcast to provide a business update at 4:30 pm ET (1:30 pm PT) that day. The call will be hosted by ...





PDF





Mar 27, 2017
SciClone To Present At Needham Healthcare Conference On April 4, 2017

FOSTER CITY, Calif., March 27, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 16th Annual Needham Healthcare Conference at 5:00 pm ET on Tuesday, April 4, 2017, at the Westin NY Grand Central Hotel in New ...





PDF





Mar 6, 2017
SciClone Reports 2016 Financial Results And 2017 Outlook

FOSTER CITY, Calif., March 6, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 2016.





Revenues: In the fourth quarter of 2016, SciClone reported revenues of $44.1 million, compared to $42.9 million for the same period in 2015. Revenues fo...





PDF





Feb 21, 2017
SciClone Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Financial Results On March 6, 2017

FOSTER CITY, Calif., Feb. 21, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2016 on Monday, March 6, 2017. SciClone will host a conference call and webcast to provide a business update at 8:30 am ET (5:30 am PT) that day. The call wil...





PDF





Feb 1, 2017
SciClone To Present At BIO CEO & Investor Conference On February 13, 2017

FOSTER CITY, Calif., Feb. 1, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 19th Annual BIO CEO & Investor Conference at 4:30 pm ET on Monday, February 13, 2017, at the Waldorf Astoria Hotel in New ...





PDF





Nov 14, 2016
SciClone Confirms Receipt Of Unsolicited Proposal From GL Capital And ABG Management

FOSTER CITY, Calif., Nov. 14, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) ("SciClone") today confirmed that it has received an unsolicited, nonbinding proposal from a consortium led by GL Capital Management GP Limited and ABG Management Limited to acquire all of the outstanding shares of SciClone not already owned by the cons...





PDF





Nov 9, 2016
SciClone Reports Third Quarter 2016 Financial Results

FOSTER CITY, Calif., Nov. 9, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended September 30, 2016.







Revenues: In the third quarter of 2016, SciClone reported revenues of $40.5 million, compared to $42.9 million for the same period in 2015. 

GAAP Diluted EPS: In...





PDF





Oct 25, 2016
SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On November 9, 2016

FOSTER CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter 2016 on Wednesday, November 9, 2016. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call ...





PDF





Sep 26, 2016
SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market

FOSTER CITY, Calif., Sept. 26, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced two important achievements in advancing the Company's clinical pipeline and development portfolio in Greater China. The first patient has been treated in the Phase 3 trial of ZADAXIN® in sepsis, a life-threatening infectious diseas...





PDF





Sep 12, 2016
Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis

PRINCETON, N.J. and FOSTER CITY, Calif., Sept. 12, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, and SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a US-based China-focused specialty pharmaceut...





PDF





Sep 1, 2016
SciClone To Present At Two Investor Conferences In September 2016

FOSTER CITY, Calif., Sept. 1, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will present a corporate overview and business update at two investor conferences in September 2016.







Friedhelm Blobel, PhD, Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global ...





PDF





Aug 9, 2016
SciClone Reports Second Quarter 2016 Financial Results

FOSTER CITY, Calif., Aug. 9, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended June 30, 2016.





 





Revenues: In the second quarter of 2016, SciClone reported revenues of $39.0 million, compared to $37.9 million for the same period in 2015. 

GAAP Diluted EP...





PDF





Jul 28, 2016
SciClone Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016

FOSTER CITY, Calif., July 28, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the second quarter 2016 on Tuesday, August 9, 2016. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call wil...





PDF





Jul 19, 2016
SciClone Provides Update On Strategic Review Process

FOSTER CITY, Calif., July 19, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today provided an update on part of the strategic review process that was previously announced in February 2016. The Company announced that it is no longer continuing active discussions with potential acquirers which were undertaken as part of its strat...





PDF





May 10, 2016
SciClone Reports First Quarter 2016 Financial Results

FOSTER CITY, Calif., May 10, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016.







Revenues: In the first quarter 2016, SciClone reported revenues of $36.5 million, compared to $33.6 million for the same period in 2015. 

GAAP Diluted EPS: In the fi...





PDF





Apr 25, 2016
SciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016

FOSTER CITY, Calif., April 25, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET (5:30 am PT) that day. The call will ...





PDF





Mar 30, 2016
SciClone To Present At Needham Healthcare Conference On April 13, 2016

FOSTER CITY, Calif., March 30, 2016 /PRNewswire/-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 15th Annual Needham Healthcare Conference at 8:00 am ET on Wednesday, April 13, 2016, at the Westin Grand Central Hotel in New Y...





PDF





Mar 10, 2016
SciClone Reports 2015 Financial Results

FOSTER CITY, Calif., March 10, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter and year ended December 31, 2015.





Revenues: Revenues for the full year 2015 were $157.3 million, compared to $134.8 million for the full year of 2014. In the fourth quarter of 2015, revenues w...





PDF





Feb 22, 2016
SciClone Pharmaceuticals To Report 2015 Financial Results On March 10, 2016

FOSTER CITY, Calif., Feb. 22, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2015 on Thursday, March 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that da...





PDF





Feb 4, 2016
SciClone Announces Final Resolution With The Securities And Exchange Commission And The Department Of Justice

FOSTER CITY, Calif., Feb. 4, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) (the "Company") today announced it has entered into a settlement agreement with the United States Securities and Exchange Commission (SEC) fully resolving the SEC's investigation into possible violations of the Foreign Corrupt Practices Act (FCPA).  Unde...





PDF





Jan 27, 2016
SciClone To Present At BIO CEO & Investor Conference On February 9, 2016

FOSTER CITY, Calif., Jan. 27, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 18th Annual BIO CEO & Investor Conference at 8:30 am ET on Tuesday, February 9, 2016, at the Waldorf Astoria Hotel in New...





PDF





Jan 11, 2016
SciClone Announces Preliminary 2015 Revenue

FOSTER CITY, Calif., Jan. 11, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its preliminary 2015 revenue results, and that it has achieved its revenue expectations for 2015. 





For 2015, the Company expects 2015 sales revenues of between $157 and $158 million, which are at the high end of the guidance o...





PDF





Dec 21, 2015
SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis

FOSTER CITY, Calif., Dec. 21, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis. SGX942 is being developed by Soligenix, Inc. (OTCQB: SNGX), which recently reported positive preliminary results fro...





PDF





Nov 17, 2015
SciClone To Present At 27th Annual Piper Jaffray Healthcare Conference On December 2, 2015

FOSTER CITY, Calif., Nov. 17, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will present a corporate overview and business update at the 27th Annual Piper Jaffray Healthcare Conference at 10:30 am ET on Wednesday, December 2, 2015, at the New York Palace Hotel...





PDF





Nov 9, 2015
SciClone Reports Third Quarter 2015 Financial Results

FOSTER CITY, Calif., Nov. 9, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended September 30, 2015.







Revenues: In the third quarter of 2015, SciClone reported revenues of $42.9 million, compared to $34.3 million for the same period in 2014.  

GAAP Diluted EPS: I...





PDF





Nov 3, 2015
SciClone To Present At Boston Biotech NY/NJ CEO Conference On November 12th

FOSTER CITY, Calif., Nov. 3, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will participate in a panel discussion at the Boston Biotech Conferences (BBC) NY/NJ CEO conference on November 12th, at the Apella in New York City. 





The conference will foc...





PDF





Oct 26, 2015
SciClone Pharmaceuticals To Report Financial Results For The Third Quarter 2015 On November 9th

FOSTER CITY, Calif., Oct. 26, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter 2015 on Monday, November 9, 2015. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call wil...





PDF





Sep 30, 2015
SciClone To Present At 2015 Aegis Capital Growth Conference On October 9th

FOSTER CITY, Calif., Sept. 30, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 2015 Aegis Capital Growth Conference at 11:25 am PT on Friday, October 9, 2015, at The Encore at Wynn Las Vegas.  





T...





PDF





Aug 27, 2015
SciClone To Present At Two Investor Conferences On September 10, 2015

FOSTER CITY, Calif., Aug. 27, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will present a corporate overview and business update at two investor conferences on September 10, 2015, in New York City.





22nd Annual NewsMakers in the Biotech Industry: pr...





PDF





Aug 10, 2015
SciClone Reports Second Quarter 2015 Financial Results

FOSTER CITY, Calif., Aug. 10, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended June 30, 2015.





 





Revenues: In the second quarter 2015, SciClone reported revenues of $37.9 million, compared to $32.5 million for the same period in 2014. 

GAAP Diluted EPS:...





PDF





Jul 23, 2015
SciClone Pharmaceuticals To Report Financial Results For The Second Quarter 2015 On August 10th

FOSTER CITY, Calif., July 23, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the second quarter 2015 on Monday, August 10, 2015. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call wil...





PDF





May 27, 2015
SciClone Pharmaceuticals and Theravance Biopharma Enter Into Development and Commercialization Agreement for VIBATIV(R) (Telavancin) in China

FOSTER CITY, CA and GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 05/27/15 -- 

SciClone Pharmaceuticals (NASDAQ: SCLN), ("SciClone"), a U.S.-based, China-focused specialty pharmaceutical company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), through an affiliate, today announced they have entered into a development and ...





PDF





May 26, 2015
SciClone to Present at Jefferies 2015 Global Healthcare Conference on June 3, 2015

FOSTER CITY, CA -- (Marketwired) -- 05/26/15 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the Jefferies 2015 Global Healthcare Conference at 10:00 am ET on Wednesday, June 3, 2015, in New York City. 

        To access...





PDF





May 11, 2015
SciClone Reports First Quarter 2015 Financial Results

FOSTER CITY, CA -- (Marketwired) -- 05/11/15 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2015.



        

            Revenues: In the first quarter 2015, SciClone reported revenues of $33.6 million, compared to $26.6 million for the same period in 2014.

         ...





PDF





Apr 30, 2015
SciClone Pharmaceuticals to Report Financial Results for the First Quarter 2015 on May 11th

FOSTER CITY, CA -- (Marketwired) -- 04/30/15 -- 

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2015 on Monday, May 11, 2015. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call will b...





PDF





Apr 6, 2015
SciClone to Present at Needham Healthcare Conference on April 14, 2015

FOSTER CITY, CA -- (Marketwired) -- 04/06/15 -- 

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 14th Annual Needham Healthcare Conference at 3:40 pm ET on Tuesday, April 14, 2015, at the Westin Grand Central Hotel in New Yo...





PDF





Mar 19, 2015
SciClone to Present at Investor and Partnering Conferences in China

FOSTER CITY, CA -- (Marketwired) -- 03/19/15 -- 

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at upcoming investor and partnering conferences taking place in China. The conferences are as follows:



        

     ...





PDF





Mar 11, 2015
SciClone Reports 2014 Financial Results and 2015 Outlook

FOSTER CITY, CA -- (Marketwired) -- 03/11/15 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 2014.



        

            Revenues: In the fourth quarter 2014, SciClone reported revenues of $41.4 million, compared to $32.7 million for the same period i...





PDF





Feb 25, 2015
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2014 on March 11th

FOSTER CITY, CA -- (Marketwired) -- 02/25/15 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2014 on Wednesday, March 11, 2015. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that...





PDF





Jan 28, 2015
SciClone to Present at BIO CEO & Investor Conference on February 9, 2015 at 11 am ET

FOSTER CITY, CA -- (Marketwired) -- 01/28/15 -- 

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 11:00 am ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in Ne...





PDF





Jan 6, 2015
SciClone Provides 2014 Financial Update and 2015 Revenue Guidance

FOSTER CITY, CA -- (Marketwired) -- 01/06/15 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reconfirmed its anticipated year-end 2014 revenue and non-GAAP earnings per share (EPS) guidance, and provided its anticipated revenue guidance for 2015, as follows. 

        For 2014, the Company:



        

            Reconfirms ex...





PDF





Dec 18, 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China

SciClone to Promote Potential Hospital Market Leaders in China,

      ANGIOMAX® (bivalirudin) and CLEVIPREX® (clevidipine)

    







        PARSIPPANY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--

      The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company

      focused on hospital care, and SciCl...





PDF





Nov 10, 2014
SciClone Reports Financial Results for the Third Quarter 2014

FOSTER CITY, CA -- (Marketwired) -- 11/10/14 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter 2014.



        

            Revenues: Revenues in the third quarter of 2014 were $34.3 million, compared to $35.2 million for the same period in 2013.

            

GAAP Basic EPS: G...





PDF





Nov 6, 2014
SciClone to Present at Jefferies Global Healthcare Conference on November 19th

FOSTER CITY, CA -- (Marketwired) -- 11/06/14 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Jefferies Global Healthcare Conference on November 19, 2014, at 4:20 pm GMT, taking place at the Waldorf Hilton Hotel i...





PDF





Oct 30, 2014
SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2014 on November 10th

FOSTER CITY, CA -- (Marketwired) -- 10/30/14 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter 2014 on Monday, November 10, 2014. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call ...





PDF





Sep 17, 2014
SciClone to Present at BioCentury NewsMakers in the Biotech Industry Conference on September 26, 2014

FOSTER CITY, CA -- (Marketwired) -- 09/17/14 -- 

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will present a corporate overview and business update at the 2014 BioCentury NewsMakers in the Biotech Industry conference at 11:30 am ET on Friday, September 26, 2014, at the Millenn...





PDF





Sep 3, 2014
SciClone to Present at Aegis 2014 Healthcare & Technology Conference on September 11, 2014

FOSTER CITY, CA -- (Marketwired) -- 09/03/14 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the Aegis Capital Corp. 2014 Healthcare & Technology Conference at 10:45 am PT on Thursday, September 11, 2014, at The Encore at W...





PDF





Aug 28, 2014
SciClone and BTG Announce That DC Bead(R) Has Been Approved by China Food and Drug Administration

FOSTER CITY, CA -- (Marketwired) -- 08/28/14 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), and its partner BTG plc (LSE: BTG), today announced that the China Food and Drug Administration has approved the registration of DC Bead® for the embolization of malignant hypervascularized tumors.

        BTG and SciClone previously entered ...





PDF





Aug 11, 2014
SciClone Reports Financial Results for the Second Quarter 2014

FOSTER CITY, CA -- (Marketwired) -- 08/11/14 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the second quarter 2014.



        

            Revenues: Revenues in the second quarter of 2014 were $32.5 million, compared to $29.3 million for the same period in 2013.

            

GAAP Basic EPS:...





PDF





Jul 31, 2014
SciClone Pharmaceuticals to Report Financial Results for the Second Quarter 2014 on August 11th

FOSTER CITY, CA -- (Marketwired) -- 07/31/14 -- 

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the second quarter 2014 on Monday, August 11, 2014. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call w...





PDF





May 27, 2014
SciClone to Present at Jefferies 2014 Global Healthcare Conference on June 3, 2014

FOSTER CITY, CA -- (Marketwired) -- 05/27/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Jefferies 2014 Global Healthcare Conference at 9:00 am ET on Tuesday, June 3, 2014, in New York City.

        To acce...





PDF





May 12, 2014
SciClone Reports Financial Results for the First Quarter 2014

FOSTER CITY, CA -- (Marketwired) -- 05/12/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the first quarter ended March 31, 2014.



        

            Revenues: Revenues for the first quarter 2014 were $26.6 million, compared to $29.8 million for the same period in 2013. On the basis of the Com...





PDF





May 5, 2014
SciClone Pharmaceuticals to Report Financial Results for the First Quarter 2014 on May 12th

FOSTER CITY, CA -- (Marketwired) -- 05/05/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2014 on Monday, May 12, 2014. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by F...





PDF





Apr 1, 2014
SciClone to Present at Needham Healthcare Conference on April 8, 2014

FOSTER CITY, CA -- (Marketwired) -- 04/01/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 13th Needham Healthcare Conference at 5:00 pm ET on Tuesday, April 8, 2014, at the Westin NY Grand Central Hotel in New York Ci...





PDF





Mar 12, 2014
SciClone Reports 2013 Financial Results and 2014 Outlook

FOSTER CITY, CA -- (Marketwired) -- 03/12/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 2013.



        

            Revenues: Revenues for the full year 2013 were $127.1 million, compared to $156.3 million for the full year of 2012. In the fourth ...





PDF





Mar 3, 2014
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 12th

FOSTER CITY, CA -- (Marketwired) -- 03/03/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2013 on Wednesday, March 12, 2014. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call...





PDF





Feb 10, 2014
SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance

FOSTER CITY, CA -- (Marketwired) -- 02/10/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Charles Meng as General Counsel and Vice President of Compliance effective February 9, 2014. Mr. Meng has more than 20 years of experience in compliance and legal affairs spanning multinational companies in diverse in...





PDF





Feb 3, 2014
SciClone to Present at BIO CEO & Investor Conference on February 11, 2014

FOSTER CITY, CA -- (Marketwired) -- 02/03/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 16th Annual BIO CEO & Investor Conference at 10:00 am ET on Tuesday, February 11, 2014, at the Waldorf Astoria Hotel in ...





PDF





Jan 24, 2014
SciClone Announces Transition From PricewaterhouseCoopers LLP to PricewaterhouseCoopers Zhong Tian LLP as Independent Registered Public Accounting Firm

FOSTER CITY, CA -- (Marketwired) -- 01/24/14 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Audit Committee of the Company's Board of Directors has appointed PricewaterhouseCoopers Zhong Tian LLP ("PwC China") to replace PricewaterhouseCoopers LLP ("PwC US") as the Company's independent registered public accounting fi...





PDF





Jan 9, 2014
SciClone Provides 2013 Financial Update and 2014 Guidance

FOSTER CITY, CA -- (Marketwired) -- 01/09/14 --

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated year-end 2013 cash position and provided its initial 2014 revenue guidance as follows. 



        

            The Company anticipates 2013 year-end cash and investments to be approximately $86 million. Excluding ...





PDF





Dec 2, 2013
SciClone to Present at Oppenheimer Healthcare Conference on December 10, 2013

FOSTER CITY, CA -- (Marketwired) -- 12/02/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 24th Annual Healthcare Conference on Tuesday, December 10, 2013, at 3:20 pm ET at the Crowne Plaza Hotel in ...





PDF





Nov 12, 2013
SciClone Reports Financial Results for the Three and Nine Months Ended September 30, 2013

FOSTER CITY, CA -- (Marketwired) -- 11/12/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter and for the nine months ended September 30, 2013.



        

            Revenues: In the third quarter 2013, SciClone reported revenues of $35.2 million, compared to $40.7 million for the ...





PDF





Nov 5, 2013
SciClone Pharmaceuticals to Report Financial Results for the Third Quarter, 2013 on November 12th

FOSTER CITY, CA -- (Marketwired) -- 11/05/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter, 2013 on Tuesday, November 12, 2013. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be host...





PDF





Sep 23, 2013
SciClone Appoints Nancy T. Chang, Ph.D., to Its Board of Directors

FOSTER CITY, CA -- (Marketwired) -- 09/23/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Nancy T. Chang, Ph.D., has been appointed a member of the Company's board of directors. Dr. Chang has more than 30 years of experience in the pharmaceutical and biotechnology industry, and has successfully developed and commerciali...





PDF





Sep 4, 2013
SciClone to Present at Four Investor Conferences in September 2013

FOSTER CITY, CA -- (Marketwired) -- 09/04/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will present a corporate overview and business update at four upcoming investor conferences in September 2013.

        Friedhelm Blobel, PhD, Chief Executive Officer, will present at the Morgan Stanley Global Healthc...





PDF





Aug 7, 2013
SciClone Reports Financial Results for the Three and Six Months Ended June 30, 2013 and Updates 2013 Guidance

FOSTER CITY, CA -- (Marketwired) -- 08/07/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the three and six months ended June 30, 2013, and updated guidance for 2013. 

        Overall revenues were $59.1 million, a decrease of $23.3 million or 28% for the first half of 2013, compared to $82.4 million ...





PDF





Aug 1, 2013
SciClone Pharmaceuticals to Report Financial Results for the Three and Six Months Ended June 30, 2013 on August 7th

FOSTER CITY, CA -- (Marketwired) -- 08/01/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the three and six months ended June 30th, 2013 on Wednesday, August 7, 2013. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day....





PDF





Jul 15, 2013
SciClone Appoints Wilson W. Cheung as Chief Financial Officer

FOSTER CITY, CA -- (Marketwired) -- 07/15/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Wilson W. Cheung as Chief Financial Officer and Senior Vice President, Finance. Mr. Cheung is an experienced senior financial and international accounting executive with broad experience spanning financial management,...





PDF





Jun 25, 2013
SciClone and Taiwan Liposome Company Enter Into a Licensing Agreement for ProFlow(R), a Novel Treatment for Peripheral Arterial Disease for the China Market

FOSTER CITY, CA and TAIPEI CITY, TAIWAN -- (Marketwired) -- 06/25/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company has entered into an agreement with Taiwan Liposome Company (TLC) granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell ProFlow...





PDF





May 28, 2013
SciClone to Present at Jefferies 2013 Global Healthcare Conference

FOSTER CITY, CA -- (Marketwired) -- 05/28/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Jefferies 2013 Global Healthcare Conference on June 5, 2013 at 12:30 pm ET at the Grand Hyatt Hotel in New York City. 
...





PDF





May 16, 2013
SciClone Reports Anticipated Financial Results for the First Quarter 2013

FOSTER CITY, CA -- (Marketwired) -- 05/16/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported its expectations regarding financial results for the quarter ended March 31, 2013. 

        Friedhelm Blobel, Ph.D., SciClone Chief Executive Officer, commented: "The accounting treatment for portions of our NovaMed promotion services...





PDF





May 16, 2013
SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China Market

FOSTER CITY, CA -- (Marketwired) -- 05/16/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company has entered into an agreement with Zensun (Shanghai) Science & Technology Co., Ltd. granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin...





PDF





Apr 8, 2013
SciClone Appoints PricewaterhouseCoopers LLP as Its Independent Registered Public Accounting Firm

FOSTER CITY, CA -- (Marketwired) -- 04/08/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the Audit Committee of the Company's Board of Directors has appointed PricewaterhouseCoopers LLP ("PwC") as its independent registered public accounting firm, effective immediately, to perform independent audit services beginning with t...





PDF





Apr 1, 2013
SciClone Reports 2012 Financial Results and 2013 Outlook

FOSTER CITY, CA -- (Marketwire) -- 04/01/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and for the year ended December 31, 2012.







Overall revenues increased $23.7 million or 18% for the full year 2012 to $156.3 million, compared to $132.6 million for the prior year, inc...





PDF





Apr 1, 2013
SciClone Pharmaceuticals to Report 2012 Financial Results and 2013 Outlook on April 1st

FOSTER CITY, CA -- (Marketwire) -- 04/01/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report 2012 financial results and 2013 outlook today, Monday, April 1, 2013. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET today. The call will be hosted by Fried...





PDF





Mar 22, 2013
SciClone Appoints Hong Zhao as Chief Executive Officer, China Operations

FOSTER CITY, CA -- (Marketwire) -- 03/22/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Hong Zhao as Chief Executive Officer, China Operations. Mr. Zhao is an accomplished, respected pharmaceutical industry executive with more than 20 years of experience in leading the commercial operations, market expans...





PDF





Mar 14, 2013
SciClone Provides Update on the Timing of Filing Its 2012 Annual Report on Form 10-K

FOSTER CITY, CA -- (Marketwire) -- 03/14/13 --

  As previously reported on February 22, 2013, SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is restating its financial statements for fiscal year 2011 and the first three quarters of fiscal 2012. The Company is in the process of completing the restatement of the financials and the Company's Annual ...





PDF





Feb 22, 2013
SciClone to Restate Financial Statements for 2012 and 2011 Periods

FOSTER CITY, CA -- (Marketwire) -- 02/22/13 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will be restating its financial statements for each of the first, second and third quarters of 2012 and financial statements for each of the second and third quarters of 2011 and for the year ended December 31, 2011. The restate...





PDF





Feb 4, 2013
SciClone to Present at BIO CEO & Investor Conference on February 12th

FOSTER CITY, CA -- (Marketwire) -- 02/04/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 2:00 pm ET at the Waldorf Astoria Hotel in New...





PDF





Jan 30, 2013
SciClone Announces Product Promotion Agreement Renewal With Key Industry Parnter Sanofi in China

FOSTER CITY, CA -- (Marketwire) -- 01/30/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has successfully negotiated renewals of its exclusive product promotion agreement with Sanofi for the China market.







Under the terms of the Sanofi agreement, SciClone, through its wholly owned subsidiary, Novamed Ph...





PDF





Jan 14, 2013
SciClone Announces Appointment of Simon Li to Its Board of Directors

FOSTER CITY, CA -- (Marketwire) -- 01/14/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Simon Li to its board of directors. Mr. Li is an accomplished and respected leader in the pharmaceutical and medical device industries in China and Asia, and brings to SciClone's board more than 30 years of experience ...





PDF





Jan 7, 2013
SciClone Provides Initial 2013 Financial Guidance

FOSTER CITY, CA -- (Marketwire) -- 01/07/13 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated 2013 initial revenue, earnings per share (EPS) and year-end cash guidance, and 2012 year-end cash position, as follows:







The Company anticipates 2013 sales revenue of $150 million - $155 million. 

The Com...





PDF





Dec 5, 2012
SciClone to Present at Oppenheimer 23rd Annual Healthcare Conference on December 13th

FOSTER CITY, CA -- (Marketwire) -- 12/05/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 23rd Annual Healthcare Conference on December 13, 2012 at 11:10 am ET at the Waldorf-Astoria Hotel in New York City...





PDF





Dec 4, 2012
SciClone Announces New ZADAXIN(R) Anti-Counterfeiting Label Wins Major Industry Award

FOSTER CITY, CA -- (Marketwire) -- 12/04/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its newly created anti-counterfeiting Pharma-Comb Void label for ZADAXIN has won the prestigious "Innovator Award" in the annual competition sponsored by the Tag and Label Manufacturers Institute (TLMI). The ZADAXIN label, which was...





PDF





Nov 12, 2012
SciClone to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th

FOSTER CITY, CA -- (Marketwire) -- 11/12/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012 at 2:00 pm ET at the Pierre Hotel in New York City.


...





PDF





Nov 9, 2012
SciClone Reports Financial Results for the Third Quarter 2012 and 2012 Outlook

FOSTER CITY, CA -- (Marketwire) -- 11/09/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter and for the nine months ended September 30, 2012. In the third quarter, ZADAXIN® sales continued to perform well, with 12% revenue increase in the quarter and 22% increase year to date compared...





PDF





Nov 8, 2012
SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2012 and 2012 Outlook on November 9th

FOSTER CITY, CA -- (Marketwire) -- 11/08/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2012 financial results and 2012 outlook on Friday, November 9, 2012. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be...





PDF





Sep 18, 2012
SciClone Announces China Government-Mandated ZADAXIN(R) Price Reduction; Anticipates Minimal Impact on Revenue and Margins

FOSTER CITY, CA -- (Marketwire) -- 09/18/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that consistent with the China government's review of pharmaceutical prices once a product has been included into the Reimbursement Drug List ("RDL"), the retail list price, or hospital pharmacy level price, of ZADAXIN® has been red...





PDF





Sep 10, 2012
SciClone Announces Management Transitions in China Operations

FOSTER CITY, CA -- (Marketwire) -- 09/10/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Mark Lotter will resign from the position of Chief Executive Officer of SciClone's China Operations at the end of this year and plans to relocate from Shanghai to London in order to spend more time with his family. At that time Mr. ...





PDF





Aug 28, 2012
SciClone Pharmaceuticals to Present at Investor Conferences in September 2012

FOSTER CITY, CA -- (Marketwire) -- 08/28/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Chief Executive Officer, will present a corporate overview and business update at the BioCentury and Thomson Reuters Newsmakers in the Biotech Industry Conference on September 7, 2012 at 10:00 am ET at the Millenni...





PDF





Aug 8, 2012
SciClone Reports Financial Results for the Second Quarter 2012

FOSTER CITY, CA -- (Marketwire) -- 08/08/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the second quarter and for the six months ended June 30, 2012. Results showed strong continued revenue growth on a quarterly and year-to-date basis for ZADAXIN®, the Company's flagship product, as well as for th...





PDF





Aug 1, 2012
SciClone Pharmaceuticals to Report Financial Results for the Second Quarter 2012 on August 8th

FOSTER CITY, CA -- (Marketwire) -- 08/01/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report second quarter 2012 financial results on Wednesday, August 8, 2012. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET that day. The call will be hosted by Frie...





PDF





May 29, 2012
SciClone Pharmaceuticals to Present at Jefferies Global Healthcare Conference

FOSTER CITY, CA -- (Marketwire) -- 05/29/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the Jefferies Global Healthcare Conference on June 5, 2012 at 9:30 am ET at the Grand Hyatt Hotel in New York City.







To acc...





PDF





May 29, 2012
SciClone Increases Stock Repurchase Program

FOSTER CITY, CA -- (Marketwire) -- 05/29/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its board of directors has approved an increase of approximately $10.5 million to the Company's stock repurchase program. The increase brings the total authorized since the program's inception in October 2011 to approximately $30.5...





PDF





May 9, 2012
SciClone Reports Financial Results for the First Quarter 2012

FOSTER CITY, CA -- (Marketwire) -- 05/09/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the first quarter ended March 31, 2012. Revenues increased by 81% for the quarter ended March 31, 2012, to $39.2 million, compared to revenues for the same period in the prior year of $21.7 million. The increases in...





PDF





May 2, 2012
SciClone Pharmaceuticals to Report Financial Results for the First Quarter 2012 on May 9th

FOSTER CITY, CA -- (Marketwire) -- 05/02/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2012 financial results on Wednesday, May 9, 2012. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET that day. The call will be hosted by Friedhe...





PDF





Apr 30, 2012
SciClone Files S-3 Registration Statement Prospectus Supplement Related to Sigma-Tau Transaction

FOSTER CITY, CA -- (Marketwire) -- 04/30/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today filed a prospectus supplement to a previously effective Form S-3 registration statement, pursuant to which approximately 9.2 million shares of SciClone Common Stock held by certain affiliates of Sigma-Tau were registered for resale under the Secu...





PDF





Apr 6, 2012
SciClone Announces Board of Directors and Officer Changes

FOSTER CITY, CA -- (Marketwire) -- 04/06/12 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the resignation of Trevor M. Jones, Ph.D., C.B.E., from the Board of Directors. Prof. Jones made this decision based on the increasing demands of his other professional obligations, including his involvement in a new business venture and...





PDF





Mar 13, 2012
SciClone Reports Financial Results for the Fourth Quarter and Year 2011 and Outlook for 2012

FOSTER CITY, CA -- (MARKET WIRE) -- 03/13/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 2011. Revenues increased by 75% for the quarter ended December 31, 2011, to $41.4 million, compared to revenues for the same period in the prior year of $23.6 million....





PDF





Mar 6, 2012
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Year Ended 2011 and Outlook for 2012 on March 13

FOSTER CITY, CA -- (MARKET WIRE) -- 03/06/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report fourth quarter and full year 2011 financial results on Tuesday, March 13, 2012. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET that day. The call will be ...





PDF





Mar 2, 2012
SciClone Announces Results of Interim Analysis of Phase 2 SCV-07 Oral Mucositis Trial

FOSTER CITY, CA -- (MARKET WIRE) -- 03/02/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that results from a pre-planned interim analysis of the phase 2b trial of SCV-07 in patients with oral mucositis (OM) indicate that the trial would not meet the pre-specified efficacy endpoints. After conferring with the study's indepe...





PDF





Feb 22, 2012
SciClone Pharmaceuticals to Present at RBC Capital Markets' Global Healthcare Conference

FOSTER CITY, CA -- (MARKET WIRE) -- 02/22/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the RBC Capital Markets' Global Healthcare Conference on February 29, 2012 at 12:00 noon ET at the New York Palace Hotel in New York Cit...





PDF





Feb 6, 2012
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference

FOSTER CITY, CA -- (MARKET WIRE) -- 02/06/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will present a corporate overview and business update at the BIO CEO & Investor Conference 2012 on February 13, 2012 at 11:00 am ET at the Waldorf-Astoria Hotel in Ne...





PDF





Jan 9, 2012
SciClone Provides 2011 Financial Update and Initial 2012 Guidance

FOSTER CITY, CA -- (MARKET WIRE) -- 01/09/12 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated full-year 2011 revenues and year-end cash position, and provided its 2012 initial revenue and year-end cash guidance as follows:







For 2011, the Company anticipates revenues of approximately $134 million (u...





PDF





Dec 15, 2011
SciClone Pharmaceuticals Announces Final Settlement of Stockholder Derivative Litigation

FOSTER CITY, CA -- (MARKET WIRE) -- 12/15/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the California Superior Court for the County of San Mateo has granted final approval of a settlement reached by the parties to the consolidated derivative lawsuits against certain of its current and former directors and officers of...





PDF





Nov 17, 2011
SciClone Pharmaceuticals Added to the NASDAQ Biotechnology Index

FOSTER CITY, CA -- (MARKET WIRE) -- 11/17/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will be added to the NASDAQ Biotechnology Index® (NASDAQ: NBI). The semi-annual re-ranking of the index will become effective prior to market opening on Monday, November 21, 2011.







"SciClone's inclus...





PDF





Nov 9, 2011
SciClone Pharmaceuticals to Present at Three Investor Conferences in November

FOSTER CITY, CA -- (MARKET WIRE) -- 11/09/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences. SciClone's executives will present a corporate overview and business update at each conference.







Cowen and Company China Opportunity Conference 

Tuesday, Nov...





PDF





Nov 8, 2011
SciClone Reports Financial Results for the Third Quarter of 2011

FOSTER CITY, CA -- (MARKET WIRE) -- 11/08/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter of 2011. Revenues for the quarter were $37.4 million compared to $22.8 million for the same period last year, an increase of $14.6 million. For the nine months ended September 30, 2011, revenues w...





PDF





Nov 1, 2011
SciClone Pharmaceuticals to Report Third Quarter 2011 Financial Results on November 8

FOSTER CITY, CA -- (MARKET WIRE) -- 11/01/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2011 financial results on Tuesday, November 8, 2011. SciClone will host a conference call to give a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, ...





PDF





Oct 12, 2011
SciClone Pharmaceuticals Announces Preliminary Settlement of Stockholder Derivative Litigation

FOSTER CITY, CA -- (MARKET WIRE) -- 10/12/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the California Superior Court for the County of San Mateo has consolidated the derivative lawsuits pending against certain of its current and former directors and officers and against SciClone Pharmaceuticals as a nominal defendan...





PDF





Oct 4, 2011
SciClone Pharmaceuticals Announces Share Repurchase Program and Reaffirms 2011 Guidance

FOSTER CITY, CA -- (MARKET WIRE) -- 10/04/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its Board of Directors has approved a share repurchase program that authorizes the company to repurchase up to $20 million of its outstanding common stock over the next 24 months. In addition, SciClone reaffirmed its previously ann...





PDF





Sep 1, 2011
SciClone Pharmaceuticals to Present at Two Investor Conferences in September

FOSTER CITY, CA -- (MARKET WIRE) -- 09/01/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Rodman & Renshaw Global Investment Conference, and UBS Global Life Sciences Conference.  SciClone's executives will present a corporate overview and business update at each con...





PDF





Aug 9, 2011
SciClone Reports Financial Results for the Second Quarter of 2011

FOSTER CITY, CA -- (MARKET WIRE) -- 08/09/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the second quarter of 2011. Revenues for the quarter were $33.1 million compared to $20.7 million for the same period last year. For the six months ended June 30, 2011, revenues were $54.8 million, compared with $3...





PDF





Jul 28, 2011
SciClone Pharmaceuticals to Report Second Quarter 2011 Financial Results on August 9

FOSTER CITY, CA -- (MARKET WIRE) -- 07/28/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report second quarter 2011 financial results on Tuesday, August 9, 2011. SciClone will host a conference call to give a business and product update at 4:30 pm ET that day. The call will be hosted by Friedhelm Blobel, P...





PDF





Jun 4, 2011
SciClone Presents New Preclinical Data Highlighting Potential Role of SCV-07 in Cancer Treatment at 2011 ASCO Annual Meeting

FOSTER CITY, CA -- (MARKET WIRE) -- 06/04/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) ("Company") today announced new data from preclinical studies of SCV-07, the Company's lead development product candidate, which showed that the compound successfully inhibited the growth of a variety of tumor cell lines in mice. These results suggest ...





PDF





Jun 2, 2011
SciClone Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference

FOSTER CITY, CA -- (MARKET WIRE) -- 06/02/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will present a corporate overview and business update at the Jefferies 2011 Global Healthcare Conference on Thursday, June 9, 2011 at 12:30 pm ET in New York City.
...





PDF





May 18, 2011
SciClone to Present New Preclinical Data on SCV-07 at 2011 ASCO Annual Meeting

FOSTER CITY, CA -- (MARKET WIRE) -- 05/18/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) ("Company") today announced that new data on SCV-07, the Company's lead development product candidate, will be presented at the 2011 American Society of Clinical Oncology ("ASCO") Annual Meeting. The new data include findings from preclinical studies ...





PDF





May 10, 2011
SciClone Pharmaceuticals Provides First Quarter Results and Updates 2011 Guidance

FOSTER CITY, CA -- (MARKET WIRE) -- 05/10/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the first quarter of 2011.

Revenues for the quarter grew 21% to $21.7 million compared with the same

period last year. SciClone reported net income of $3.8 million, or $0.08

per share on a basic and diluted...





PDF





Apr 29, 2011
SciClone Pharmaceuticals to Report First Quarter 2011 Results on May 10

FOSTER CITY, CA -- (MARKET WIRE) -- 04/29/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2011 results on Tuesday, May 10, 2011. SciClone is hosting a conference call at 8:30 am ET to provide a financial update. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, Gary...





PDF





Apr 19, 2011
SciClone Acquires NovaMed Pharmaceuticals Further Establishing It as a Leading China-Focused Specialty Pharmaceutical Company

FOSTER CITY, CA -- (MARKET WIRE) -- 04/19/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) ("Company") today announced that it has acquired NovaMed Pharmaceuticals Inc., ("NovaMed") a China-based specialty pharmaceutical company. The acquisition brings additional broad sales and marketing, as well as regulatory and extensive business capabil...





PDF





Mar 31, 2011
SciClone Pharmaceuticals Provides Fourth Quarter and Year End 2010 Results and 2011 Guidance

FOSTER CITY, CA -- (MARKET WIRE) -- 03/31/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the fourth quarter and year ended December 31, 2010. Revenues for the fourth quarter of 2010 grew to $23.6 million, or an increase of 30% compared to revenues of 18.1 million in the fourth quarter of 2009. Net income for the ...





PDF





Mar 31, 2011
SciClone Pharmaceuticals to Provide Financial Update on April 1

FOSTER CITY, CA -- (MARKET WIRE) -- 03/31/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to provide a financial update on Friday, April 1, 2011. SciClone will host a conference call at 8:30 am ET on that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Gary Titus, Senior Vice Pre...





PDF





Mar 16, 2011
SciClone Reports Preliminary Financial Results for the Fourth Quarter and Year End 2010

FOSTER CITY, CA -- (MARKET WIRE) -- 03/16/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported preliminary results for the fourth quarter and year

ended December 31, 2010. Revenues for the fourth quarter of 2010 grew to

$23.6 million, or an increase of 30% compared to the fourth quarter of

2009.  For the year ended Decemb...





PDF





Mar 1, 2011
SciClone Pharmaceuticals to Present at Two Investor Conferences in March

FOSTER CITY, CA -- (MARKET WIRE) -- 03/01/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Cowen Healthcare Conference and Rodman & Renshaw Annual China Investment Conference. SciClone's executives will present a corporate overview and business update at each confere...





PDF





Feb 28, 2011
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results for 2010 on March 16

FOSTER CITY, CA -- (MARKET WIRE) -- 02/28/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report fourth quarter and year-end results for 2010 on Wednesday, March 16, 2011. SciClone will host a conference call to give a business update and guidance for 2011 at 4:30 pm ET that day. The call will be hosted by ...





PDF





Feb 8, 2011
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference

FOSTER CITY, CA -- (MARKET WIRE) -- 02/08/11 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will present a corporate overview and business update at the BIO CEO & Investor Conference 2011 on February 15, 2011 at 10:00 am ET in New York City.







T...





PDF





Jan 11, 2011
SciClone Initiates Phase 2b Study of SCV-O7 for Treatment of Oral Mucositis

FOSTER CITY, CA -- (MARKET WIRE) -- 01/11/11 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and...





PDF





Dec 15, 2010
SciClone Announces Topline Results From Phase 2b Clinical Trial of SCV-07 for Treatment of Chronic Hepatitis C

FOSTER CITY, CA -- (MARKET WIRE) -- 12/15/10 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced topline results from the Company's phase 2b clinical trial of SCV-07 for the treatment of hepatitis C (HCV). The study evaluated the safety and immunomodulatory effects of SCV-07 as a monotherapy and in combination with ribavirin in re...





PDF





Nov 10, 2010
SciClone Pharmaceuticals to Present at Two Investor Conferences in November

FOSTER CITY, CA -- (MARKET WIRE) -- 11/10/10 --

  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Lazard Capital Markets Healthcare Conference and Piper Jaffray Health Care Conference. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a...





PDF





Nov 8, 2010
SciClone Reports Financial Results for the Third Quarter of 2010 and Provides Updated Guidance for the Full Year

FOSTER CITY, CA -- (MARKET WIRE) -- 11/08/10 --

 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter of 2010. As

reported on October 12, 2010, product revenues from sales of ZADAXIN® were

$22.8 million, an increase of 32.5% compared with revenues of $17.2 million

for the same period last ...





PDF





Oct 12, 2010
SciClone Announces Continued Topline Growth and Strong Cash Position in the Third Quarter of 2010

FOSTER CITY, CA, Oct 12, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that product sales for the third quarter 2010 rose 32.5% over the prior year quarter to reach $22.8 million (unaudited) compared with $17.2 million for the same period last year. For the nine months ended September 30,...





PDF





Oct 5, 2010
Debt Financing Facility Increased to $15 Million

FOSTER CITY, CA, Oct 05, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Silicon Valley Bank (SVB), the primary subsidiary of SVB Financial Group (NASDAQ: SIVB), has increased the existing debt financing facility ("the Bank Line") to the Company's operating subsidiaries. The new Bank L...





PDF





Sep 29, 2010
SciClone Identifies Unique Genetic Markers Associated With Patient Response to SCV-07 Treatment in Oral Mucositis

FOSTER CITY, CA, Sep 29, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company's phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (...





PDF





Sep 13, 2010
SciClone Pharmaceuticals to Present at Two Investor Conferences in September

FOSTER CITY, CA, Sep 13, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Rodman & Renshaw Global Investment Conference, and UBS Global Life Sciences Conference. SciClone's executives will present a corporate overview and business up...





PDF





Aug 9, 2010
SciClone Reports Financial Results for the Second Quarter of 2010 and Provides Updated Guidance for the Full Year

FOSTER CITY, CA, Aug 09, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the second quarter of 2010. Product revenues from sales of ZADAXIN were $20.7 million, a decrease of 6% compared with revenues of $22.0 million for the same period last year. As previously indicate...





PDF





Jul 29, 2010
SciClone Pharmaceuticals to Present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on August 5

FOSTER CITY, CA, Jul 29, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the upcoming BMO Capital Markets 10th Annual Focus on Healthcare Conference. Gary Titus, Senior Vice President and Chief Financial Officer, will present a corporate overview and business update ...





PDF





Jul 26, 2010
SciClone Pharmaceuticals to Report Second Quarter 2010 Financial Results and Provide a Business Update on August 9

FOSTER CITY, CA, Jul 26, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report second quarter 2010 financial results on Monday, August 9, 2010. SciClone will host a conference call to give a business and product update at 4:30 pm ET that day. The call will be hosted by Fri...





PDF





Jun 30, 2010
SciClone and Sigma-Tau Announce Final Data From Clinical Trial of ZADAXIN as H1N1 Vaccine Enhancer

FOSTER CITY, CA, Jun 30, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced final results from a clinical study evaluating the potential of ZADAXIN(R) (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria(R) from...





PDF





Jun 3, 2010
SciClone Pharmaceuticals to Present at Three Investor Conferences in June

FOSTER CITY, CA, Jun 03, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences: Jefferies 2010 Global Life Sciences Conference, Needham Annual Healthcare Conference, and ThinkEquity Mid-Year Check up on Healthcare Conference. SciClone's ...





PDF





May 17, 2010
SciClone Provides Clinical Program Update for SCV-07 for the Prevention of Oral Mucositis in Patients With Advanced Head and Neck Cancer

FOSTER CITY, CA, May 17, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced further topline results from the company's phase 2 proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer -- a painful and debil...





PDF





May 10, 2010
SciClone Pharmaceuticals to Present at Two Investor Conferences in May

FOSTER CITY, CA, May 10, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Rodman & Renshaw Annual London Investment China Conference, and the Oppenheimer Annual China Dragon Call Conference. SciClone's executives will present a corpo...





PDF





May 6, 2010
SciClone Reports Financial Results for the First Quarter of 2010

FOSTER CITY, CA, May 06, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the first quarter of 2010. Revenues for the quarter grew 19% to $18.0 million compared with the same period last year. SciClone reported net income of $4.2 million, or $0.09 per share, compared wit...





PDF





Apr 26, 2010
SciClone Pharmaceuticals to Report First Quarter 2010 Results on May 6

FOSTER CITY, CA, Apr 26, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2010 results on Thursday, May 6, 2010. SciClone will host a conference call to give a business and product update at 4:30 pm ET that day. The call will be hosted by Friedhelm Blobe...





PDF





Mar 30, 2010
SciClone Announces Topline Results From Phase 2 Clinical Trial of SCV-07 for Prevention of Oral Mucositis

FOSTER CITY, CA, Mar 30, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced topline results from the company's phase 2 clinical trial of SCV-07 for the prevention of severe oral mucositis (OM) (World Health Organization, WHO scale, grades 3 to 4) -- a painful, debilitating, and costly toxicity...





PDF





Mar 24, 2010
ondansetron RapidFilm(TM) Approved in 16 European Countries

FOSTER CITY, CA, Mar 24, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the European approval of ondansetron RapidFilm(TM), co-developed by APR Applied Pharma Research s.a. ("APR"), and Labtec GmbH and licensed to BioAlliance Pharma s.a. for European Union ("EU") countries. BioAlliance was...





PDF





Mar 2, 2010
SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates

FOSTER CITY, CA, Mar 02, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the fourth quarter and year ended December 31, 2009. Revenues for the fourth quarter of 2009 grew to $18.1 million, or 18% compared to the fourth quarter of 2008. Net income for the fourth quarter of 2009 wa...





PDF





Mar 1, 2010
SciClone Pharmaceuticals to Present at Three Investor Conferences in March

FOSTER CITY, CA, Mar 01, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences: Rodman & Renshaw Annual China Investment Conference, Cowen Healthcare Conference, and Roth Growth Stock Conference. SciClone's executives will present a corp...





PDF





Feb 18, 2010
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 2, 2010

FOSTER CITY, Calif., Feb 18, 2010 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it 
      plans to report fourth quarter and year-end results for 2009 on Tuesday, 
      March 2, 2010. SciClone will host a conference call to give a business 
      and product update and guidance for 2010 at 4:30 pm ET that...





PDF





Feb 8, 2010
SciClone and Sigma-Tau Announce Additional Positive Results in Clinical Study Examining ZADAXIN's Ability to Enhance Response to H1N1 Vaccine

FOSTER CITY, CA and ROME, Feb 08, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN(R) (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vacci...





PDF





Feb 2, 2010
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference

FOSTER CITY, CA, Feb 02, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will present a corporate overview and business update at the BIO CEO & Investor Conference 2010 on February 9, 2010 at 1:30 p.m. ET in New York City....





PDF





Jan 12, 2010
SciClone and Sigma-Tau Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine

FOSTER CITY, CA and ROME, Jan 12, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A. have received initial topline results in a clinical study evaluating the potential of ZADAXIN(R) (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vacci...





PDF





Jan 11, 2010
SciClone Provides 2009 Financial Update and Initial 2010 Sales Revenue Guidance

FOSTER CITY, CA, Jan 11, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its full year 2009 sales revenue, 2010 sales revenue guidance and its year-end cash position as follows: 


--  For 2009, the company anticipates revenues of approximately $72.4
    million (unaudited), a 34% incre...





PDF





Nov 30, 2009
SciClone Announces Commencement and Complete Enrollment of Clinical Study Examining ZADAXIN's Ability to Enhance the H1N1 Vaccine Led by European Partner, Sigma-Tau

FOSTER CITY, CA, Nov 30, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Rome-based development partner Sigma-Tau, S.p.A., has initiated a
pilot study in Italy to evaluate ZADAXIN's® (thymalfasin) ability
to enhance immune response to the MF59 adjuvanted H1N...





PDF





Nov 23, 2009
SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07

FOSTER CITY, CA, Nov 23, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
patient enrollment is complete ahead of schedule for its phase 2
trial of SCV-07 -- a small molecule synthetic peptide with
immunomodulating properties -- for the treatment of severe oral
mucositis (OM) in patients with he...





PDF





Nov 23, 2009
SciClone Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference

FOSTER CITY, CA, Nov 23, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at the upcoming Piper Jaffray Annual Healthcare
Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's
President and Chief Executive Officer, will present a corporate
overview and business update ...





PDF





Nov 12, 2009
SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings

FOSTER CITY, CA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced
presentations of multiple abstracts demonstrating SCV-07's anti-tumor
immunomodulating properties at two upcoming events: Cold Spring
Harbor Laboratory's Harnessing Immunity to Prevent and Treat Disease
meeting; and the America...





PDF





Nov 9, 2009
SciClone Reports Financial Results and Provides Commercial and Pipeline Updates for the Third Quarter of 2009

FOSTER CITY, CA, Nov 09, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported
financial results for the third quarter of 2009. Revenues for the
quarter grew 20% to $17.2 million compared with the same period last
year. SciClone reported net income of $2.1 million or $0.04 per share
on a basic and diluted ...





PDF





Nov 3, 2009
SciClone Pharmaceuticals to Present at Two November Investor Conferences

FOSTER CITY, CA, Nov 03, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at two upcoming investor conferences in New York
City: Merriman Investor Summit, and Lazard Capital Markets 6th Annual
Healthcare Conference. Gary Titus, SciClone's Senior Vice President
and Chief Financial...





PDF





Oct 28, 2009
SciClone Announces Corporate Restructuring and Workforce Reduction

FOSTER CITY, CA, Oct 28, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced a
corporate restructuring that will reduce its U.S.-based workforce by
approximately 17%, primarily in research and development. This
restructuring follows the discontinuation of SciClone's RP101 phase 2
clinical trial annou...





PDF





Oct 26, 2009
SciClone Pharmaceuticals to Report Third Quarter 2009 Results on November 9

FOSTER CITY, Calif., Oct 26, 2009 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2009 results on Monday, November 9. SciClone will host a conference call to give a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., Preside...





PDF





Oct 21, 2009
SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C

FOSTER CITY, CA, Oct 21, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
enrollment of its first patient at the Atlanta Gastroenterology
Associates in Atlanta, GA, in a phase 2 trial of SCV-07 for the
treatment of hepatitis C (also known as HCV). This multicenter,
multidose, open-label study ...





PDF





Oct 2, 2009
Phase 2 Trial of RP101 in Late-Stage Pancreatic Cancer Discontinued

FOSTER CITY, CA, Oct 02, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the discontinuation of the investigational treatments under its randomized, placebo-controlled, double-blind Phase 2 trial that is evaluating RP101 -- a nucleoside analog known as BvdU -- for the treatment of late-stage pancreat...





PDF





Sep 9, 2009
SciClone Pharmaceuticals to Present at Two September Investor Conferences

FOSTER CITY, CA, Sep 09, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: ThinkEquity's Annual Growth Conference (G6) in San Francisco, and the UBS Global Life Sciences Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President...





PDF





Sep 4, 2009
SciClone Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference

FOSTER CITY, CA, Sep 04, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business upd...





PDF





Aug 4, 2009
SciClone Reports Financial Results and Provides Pipeline Update for the Second Quarter of 2009

FOSTER CITY, CA, Aug 04, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported
financial results for the second quarter of 2009. Revenues for the
quarter grew 59% to $22.0 million compared with the same period in
2008. SciClone reported net income of $7.3 million or $0.16 per share
on a basic and diluted b...





PDF





Jul 31, 2009
SciClone Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

FOSTER CITY, CA, Jul 31, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and busines...





PDF





Jul 30, 2009
SciClone Pharmaceuticals Announces Appointment of Jon S. Saxe as Chairman of Board of Directors

FOSTER CITY, CA, Jul 30, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Dean S. Woodman, current Chairman of the Board of Directors, is stepping down from that role while continuing as a board member. Jon S. Saxe, a SciClone board member of many years, will succeed him as Chairman.
"Dea...





PDF





Jul 27, 2009
SciClone Pharmaceuticals Expands Portfolio by Licensing Ondansetron RapidFilm for Chinese Market

FOSTER CITY, CA and BALERNA, SWITZERLAND, Jul 27, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and APR Applied Pharma Research S.A. ("APR") today announced that they have entered into an exclusive licensing agreement granting SciClone the commercialization rights for APR's innovative anti-nausea drug ondansetron ...





PDF





Jul 22, 2009
SciClone Pharmaceuticals to Report Second Quarter 2009 Results on August 4

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 22, 2009--
      SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) today announced that it
      plans to report second quarter 2009 results on Tuesday, August 4, 2009.
      S...





PDF





Jun 30, 2009
SciClone Pharmaceuticals, Inc. Added to Russell 3000(R) Index

FOSTER CITY, CA, Jun 30, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it has been added to the Russell 2000® and Russell 3000 Indexes.
The Russell 3000 Index measures the performance of the largest 3000
U.S. companies and is a combination of the Russel...





PDF





May 20, 2009
SciClone Pharmaceuticals, Inc. Files Shelf Registration Statement

FOSTER CITY, CA, May 20, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) has filed a shelf
registration statement on Form S-3 with the Securities and Exchange
Commission ("SEC").  When the shelf registration statement is
declared effective by the SEC, it will allow SciClone to periodically
sell, in one or more offe...





PDF





May 11, 2009
SciClone Reports Financial Results for the First Quarter of 2009

FOSTER CITY, CA, May 11, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported
financial results for the first quarter of 2009. Revenues for the
quarter grew 42% to $15.1 million over the same period last year.
SciClone reported net income of $0.1 million or $0.00 per share on a
basic and diluted basis, co...





PDF





Apr 29, 2009
SciClone Pharmaceuticals to Report First Quarter 2009 Results on May 11

FOSTER CITY, CA, Apr 29, 2009 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report first quarter 2009 results on Monday, May 11,
2009. SciClone will host a conference call to give a business and
product update at 4:30 pm ET that day. The call will be hosted by
Friedhelm Blobel, Ph.D.,...





PDF





Mar 31, 2009
SciClone and Sigma Tau Reach Agreement to Resolve Director Election Contest for 2009 Annual Meeting of SciClone Stockholders

FOSTER CITY, CA, Mar 31, 2009 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) ("SciClone") announced
today that SciClone and Sigma-Tau Finanziaria, S.p.A. and certain of
its affiliated individuals and corporations (referred to in this
press release collectively as "Sigma-Tau") have entered into a
definitive agreemen...





PDF





Mar 9, 2009
SciClone Completes Enrollment Ahead of Schedule in Phase 2 Trial for RP101 in Late-Stage Pancreatic Cancer Patients

FOSTER CITY, CA, Mar 09, 2009 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
enrollment has been completed ahead of schedule in the Company's
phase 2 clinical trial for RP101 in patients with late-stage
pancreatic cancer. Results from a previous phase 1 study in 22
late-stage pancreatic cancer ...





PDF





Mar 3, 2009
SciClone Reports Financial Results for the Fourth Quarter and Year-End 2008

FOSTER CITY, CA, Mar 03, 2009 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the fourth quarter and year ended December 31, 2008. The fourth
quarter 2008 revenues grew 53% to $15,317,000 over the same period
last year, and net loss declined to $3,143,000 or $0.07 per share on
a basic and ...





PDF





Feb 23, 2009
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 3, 2009

FOSTER CITY, CA, Feb 23, 2009 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report fourth quarter and year-end results for 2008 on
Tuesday, March 3, 2009. SciClone will host a conference call to give
a business and product update and guidance for 2009 at 11:00 am ET
that day. The call...





PDF





Feb 9, 2009
SciClone Issues Guidance, Breaking Through to Profitability for the Full Year of 2009

FOSTER CITY, CA, Feb 09, 2009 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
revenues for 2008 rose 46% over the prior year to reach a record $54
million (unaudited). SciClone ended 2008 with more than $27 million
in cash. The company also issued guidance for continued double-digit
revenue grow...





PDF





Feb 2, 2009
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference

FOSTER CITY, CA, Feb 02, 2009 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will
present a corporate overview at the BIO CEO & Investor Conference
2009 on February 9, 2009 at 12:00 p.m. ET in New York City. Dr.
Blobel plans to di...





PDF





Jan 5, 2009
SciClone Acknowledges Receipt of Director Nomination Notice From Affiliate of Sigma-Tau

FOSTER CITY, CA, Jan 05, 2009 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced today that
it has received from Defiante Farmaceutica S.A, a company controlled
by Sigma-Tau Finanziaria S.p.A, a notice of intention to nominate
four candidates for election to SciClone's seven-person board at the
2009...





PDF





Dec 22, 2008
SciClone Announces First Patient Enrolled in Phase 2 Clinical Trial Using SCV-07 to Prevent Oral Mucositis

FOSTER CITY, CA, Dec 22, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
enrollment of its first patient in its phase 2, multi-center,
randomized, double-blind, placebo-controlled study to assess the
safety and efficacy of SCV-07 for prevention of oral mucositis (OM)
in patients re...





PDF





Dec 2, 2008
SciClone Pharmaceuticals Appoints Gary Titus as Chief Financial Officer

FOSTER CITY, CA, Dec 02, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Gary Titus as Chief Financial Officer and Senior Vice
President, Finance, effective December 8, 2008. In this position, Mr.
Titus will use his significant biotechnology industry experience to
...





PDF





Nov 19, 2008
SciClone Secures Six Million in Debt Financing From Silicon Valley Bank

FOSTER CITY, CA, Nov 19, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Silicon Valley Bank will provide the company's operating subsidiaries
a $6,000,000 debt financing ("the Bank Line"). The Bank Line will be
used to provide additional working capital to support SciClone's
g...





PDF





Nov 17, 2008
SciClone Reaches Agreement With FDA on Special Protocol Assessment for Phase 3 Thymalfasin Trial in Stage IV Melanoma

FOSTER CITY, CA, Nov 17, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
the Company and the U.S. Food and Drug Administration (FDA) have
reached agreement on the design of a phase 3 registration trial for
thymalfasin as a potential treatment for stage IV melanoma.
Based on ...





PDF





Nov 6, 2008
SciClone Reports 52 percent Revenue Growth and a Profit in the Third Quarter of 2008

FOSTER CITY, CA, Nov 06, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the third quarter ended September 30, 2008. Among the financial
results reported by the biopharmaceutical company, revenue from
product sales grew 52% to $14,328,000 over the same period last year,
an...





PDF





Nov 5, 2008
SciClone and Sigma-Tau Report Phase 3 Hepatitis C Trial Results

FOSTER CITY, CA, Nov 05, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A.
today announced top-line results from a large, randomized, phase 3
clinical trial evaluating thymalfasin in combination with pegylated
interferon alpha-2a (peg-IFN-2a) and ribavirin (RBV) as a treatment
fo...





PDF





Oct 27, 2008
SciClone Pharmaceuticals to Report Third Quarter 2008 Results on November 6, 2008

FOSTER CITY, CA, Oct 27, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will report results for the third quarter ended September 30, 2008
and host a conference call on Thursday, November 6, 2008.
Management will review operating results for the third quarter 2008
and...





PDF





Sep 22, 2008
SciClone Provides Promising Results From Its Phase 2A Clinical Trial Using SCV-07 as a Monotherapy in Patients With Chronic Hepatitis C Infection

FOSTER CITY, CA, Sep 22, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced
promising results from its proof-of-concept phase 2 clinical trial
using its proprietary, immunomodulatory compound SCV-07 as a sole
agent administered to patients chronically infected with the
hepatitis C virus (...





PDF





Sep 16, 2008
SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference

FOSTER CITY, CA, Sep 16, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at the UBS Global Life Sciences Conference at the
Grand Hyatt New York. Friedhelm Blobel, Ph.D., SciClone's President
and Chief Executive Officer, will present a corporate overview and
busines...





PDF





Aug 7, 2008
SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development

FOSTER CITY, CA, Aug 07, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
appointment of Jeffery Lange as Vice President, Business Development
effective August 11, 2008. In this position, Mr. Lange will leverage
his significant biopharmaceutical industry experience to lead
business ...





PDF





Jul 29, 2008
SciClone Reports Results for the Second Quarter of 2008

FOSTER CITY, CA, Jul 29, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the second quarter ended June 30, 2008.
"We achieved outstanding revenue growth in our China business in the
second quarter. Consolidated sales of ZADAXIN® (thymal...





PDF





Jul 25, 2008
SciClone Pharmaceuticals to Report Second Quarter 2008 Results on July 29, 2008

FOSTER CITY, CA, Jul 25, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report results for the second quarter ended June 30, 2008
and host a conference call on Tuesday, July 29, 2008.
Management will review operating results for the second quarter 2008
and give a b...





PDF





Jun 26, 2008
SciClone and Sigma-Tau Provide Update on Phase 3 Hepatitis C Study

FOSTER CITY, CA, Jun 26, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A.
today announced that all 553 enrolled patients successfully completed
a Phase 3 trial. After 48 weeks of therapy, all patients responding
to treatment have now completed their 24-week follow-up. The
unblinded...





PDF





Jun 6, 2008
SciClone Pharmaceuticals to Hold Annual Stockholders Meeting June 10, 2008

FOSTER CITY, CA, Jun 06, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will hold its Annual Meeting of Stockholders on Tuesday, June 10,
2008 at 10:00 a.m. Pacific time.  The meeting will be held at the San
Mateo Marriott in San Mateo, CA.  Registered stockholders are
encoura...





PDF





May 8, 2008
SciClone Reports Results for the First Quarter 2008

FOSTER CITY, CA, May 08, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the first quarter ended March 31, 2008.
"Over the course of the first quarter, product revenues from
ZADAXIN® sales increased 23% to exceed $10 million, and for t...





PDF





May 2, 2008
SciClone Pharmaceuticals to Report First Quarter 2008 Results on May 8, 2008

FOSTER CITY, CA, May 02, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report first quarter 2008 results and host a conference
call on Thursday, May 8, 2008.
Management will review operating results for the first quarter 2008
and give a business update.  The confe...





PDF





Apr 16, 2008
SciClone to Hold Symposium on New Therapies in Liver Cancer and Hepatitis C Virus

FOSTER CITY, CA, Apr 16, 2008 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced thatit will hold a symposium titled "New Therapies in Liver Cancer and
Hepatitis" during the 43rd annual meeting of the European Association
for the Study of the Liver (EASL) in Milan, Italy. SciClone and
Sigma-Tau...





PDF





Nov 13, 2007
SciClone Reports Third Quarter 2007 Results

FOSTER CITY, CA, Nov 13, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the third quarter ended September 30, 2007.  For the third
quarter 2007, product revenues from the sale of ZADAXIN®
(thymalfasin), SciClone's lead product, increased...





PDF





Nov 6, 2007
SciClone to Present at BIO-Europe 2007 Conference on November 14, 2007

FOSTER CITY, CA, Nov 06, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will
present a corporate overview at BIO-Europe 2007, an international
partnering conference.  The presentation is scheduled for November
14, 20...





PDF





Oct 30, 2007
SciClone Pharmaceuticals to Report Third Quarter 2007 Results on November 13, 2007

FOSTER CITY, CA, Oct 30, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report third quarter 2007 results and host a conference
call on Tuesday, November 13, 2007.
The conference call will contain forward-looking statements. 
Financial and statistical information t...





PDF





Sep 13, 2007
SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference

SAN MATEO, CA, Sep 13, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at the UBS Global Life Sciences Conference at the
Grand Hyatt New York.  Friedhelm Blobel, Ph.D., SciClone's President
and Chief Executive Officer, will present a corporate overview and
business...





PDF





Aug 7, 2007
SciClone Reports Second Quarter 2007 Results

SAN MATEO, CA, Aug 07, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the second quarter ended June 30, 2007. For the second quarter
2007, product revenues from the sale of ZADAXIN® (thymalfasin),
SciClone's lead product, increased by 13...





PDF





Jul 31, 2007
SciClone Pharmaceuticals to Report Second Quarter 2007 Results on August 7, 2007

SAN MATEO, CA, Jul 31, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report second quarter 2007 results and host a conference
call on Tuesday, August 7, 2007.
The conference call will contain forward-looking statements.
Financial and statistical information to be ...





PDF





Jun 27, 2007
SciClone Initiates Phase 2 Clinical Trial Using SCV-07 to Treat Hepatitis C Patients

SAN MATEO, CA, Jun 27, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced it has
initiated a proof-of-concept phase 2 clinical trial using its
proprietary compound SCV-07 as a sole agent to treat patients
infected with the hepatitis C virus (HCV).  The trial is designed to
evaluate the th...





PDF





Jun 4, 2007
SciClone's SCV-07 Inhibits Melanoma Tumor Growth in Animal Model Study

SAN MATEO, CA, Jun 04, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported data
showing that SCV-07 inhibits the growth of melanoma tumors in an
animal model study.  These data were the subject of an abstract
accepted for the Annual Meeting of the American Society of Clinical
Oncology in Ch...





PDF





Jun 4, 2007
SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial

SAN MATEO, CA, Jun 04, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A
today announced that SciClone's lead product candidate thymalfasin
(ZADAXIN®, thymosin alpha 1) achieved its primary endpoint in a
phase 2 clinical trial treating patients di...





PDF





May 8, 2007
SciClone Reports First Quarter 2007 Results

SAN MATEO, CA, May 08, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the first quarter ended March 31, 2007.
"Over the course of the first quarter, we continued to increase our
sales of ZADAXIN® in China, and are in the process of ex...





PDF





May 1, 2007
SciClone Pharmaceuticals to Report First Quarter Results on May 8, 2007

SAN MATEO, CA, May 01, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
plans to report first quarter 2007 results and host a conference call
on Tuesday, May 8, 2007.
The conference call will contain forward-looking statements. 
Financial and statistical information to be dis...





PDF





Apr 27, 2007
SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO

SAN MATEO, CA, Apr 27, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
the following abstracts have been accepted for the Annual Meeting of
the American Society of Clinical Oncology in Chicago, Illinois on
June 1-5, 2007:
ZADAXIN® (thymalfa...





PDF





Apr 26, 2007
SciClone Acquires Clinical-Stage Pancreatic Cancer Compound

SAN MATEO, CA, Apr 26, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it has acquired the exclusive rights in the United States and Canada
to develop and commercialize RP101, a clinical-stage compound for the
treatment of cancer.  SciClone acquired the rights from Resistys,
Inc.,...





PDF





Mar 15, 2007
SciClone Reports Fourth Quarter and Year End 2006 Results

AN MATEO, CA, Mar 15, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the fourth quarter and full year ended December 31, 2006.
"We achieved several substantial clinical, financial and regulatory
milestones over the course of the last twelve months.  We reported
positive ...





PDF





Mar 13, 2007
SciClone Pharmaceuticals to Report Fourth Quarter and Year End Results on March 15, 2007

SAN MATEO, CA, Mar 13, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report fourth quarter and year end 2006 results and host
a conference call on Thursday, March 15, 2007.
The conference call will contain forward-looking statements. 
Financial and statistical inf...





PDF





Feb 8, 2007
SciClone Pharmaceuticals to Present at BIO CEO and Investor Conference on February 14, 2007

SAN MATEO, CA, Feb 08, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will
present a corporate overview at the BIO CEO and Investor Conference
2007 on February 14, 2007 at 11:15 a.m. ET, in New York, New York. 
To ac...





PDF





Feb 5, 2007
SciClone Announces Accelerated Clinical Development Plans for SCV-07

SAN MATEO, CA, Feb 05, 2007 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
based on an extensive review of positive human clinical trial and
animal model results, it will initiate a controlled phase 2
dose-ranging clinical trial using its proprietary compound SCV-07 in
the second quar...





PDF





Dec 28, 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial

SAN MATEO, CA, Dec 28, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its European
partner Sigma-Tau S.p.A. today announced that full patient enrollment
is complete for its phase 3 clinical trial evaluating the use of
ZADAXIN® (thymalfasin or thymosin alpha 1)...





PDF





Dec 28, 2006
SciClone Submits Regulatory Application for DC Bead in China

SAN MATEO, CA, Dec 28, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it has submitted a regulatory application to the Chinese State Food
and Drug Administration (SFDA) for approval to market the DC
Bead, a product for the treatment of liver...





PDF





Dec 22, 2006
SciClone Pharmaceuticals Adopts Stockholders Rights Plan

SAN MATEO, CA, Dec 22, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced today that
its Board of Directors has adopted a Stock Purchase Rights Plan
designed to enable all SciClone stockholders to realize the full
value of their investment and to provide for fair and equal treatment
for all Sci...





PDF





Dec 22, 2006
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial

SAN MATEO, CA, Dec 22, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A.
today announced positive interim survival data from a large phase 2
trial treating patients with stage IV malignant melanoma, the most
advanced form of this cancer. Data from the first four arms of this
ongoing...





PDF





Nov 20, 2006
Alfred Rudolph, M.D. Is Leaving as Chief Operating Officer

SAN MATEO, CA, Nov 20, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that Alfred
Rudolph, M.D., Chief Operating Officer, is leaving the Company,
effective November 17, 2006.  The Company is actively working to
identify a successor.  In the interim, Friedhelm Blobel, Ph.D.,
President and...





PDF





Nov 1, 2006
SciClone Pharmaceuticals to Present at the BIO-Europe 12th Annual International Partnering Conference

SAN MATEO, CA, Nov 01, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at the BIO-Europe 12th Annual International
Partnering Conference at the Congress Center Sued Stadthalle in
Duesseldorf, Germany on November 8, 2006 at 10:30 a.m. CET. 
Friedhelm Blobel, Ph.D...





PDF





Oct 31, 2006
SciClone Reports Third Quarter 2006 Results

SAN MATEO, CA, Oct 31, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the third quarter ended September 30, 2006.  For the third
quarter 2006, revenues from the sale of ZADAXIN®, SciClone's lead
product, increased by 18% to $8,270,000...





PDF





Oct 25, 2006
SciClone Pharmaceuticals to Present at the Rodman & Renshaw Healthcare Conference

SAN MATEO, CA, Oct 25, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at the Rodman & Renshaw Healthcare Conference on
Monday, November 6, 2006 at 12:50 pm EST.

To access the live audio webcast of the presentation, log on through
a link located in ...





PDF





Oct 19, 2006
SciClone Pharmaceuticals to Report Third Quarter 2006 Results on October 31, 2006

AN MATEO, CA, Oct 19, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report third quarter 2006 results and host a conference
call on Tuesday, October 31, 2006.

The conference call will contain forward-looking statements.
Financial and statistical information ...





PDF





Oct 17, 2006
SciClone Pharmaceuticals to Webcast Presentation at BIO InvestorForum Conference

SAN MATEO, CA, Oct 17, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will
present a corporate overview at the BIO InvestorForum 2006 Conference
on Wednesday, October 18, 2006 at 2:20 p.m. PDT in San Francisco,
Ca...





PDF





Sep 25, 2006
SciClone's New CEO Unveils Focused Global Strategic Vision

SAN MATEO, CA, Sep 25, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that
Friedhelm Blobel, Ph.D., SciClone's recently appointed President and
Chief Executive Officer, will unveil a focused global strategic
vision and upcoming milestones during his presentation at the UBS
Global Life Sc...





PDF





Sep 18, 2006
SciClone and Sigma-Tau Present Encouraging Interim Phase 2 Metastatic Malignant Melanoma Response Data

SAN MATEO, CA, Sep 18, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A
today reported interim data showing that the addition of ZADAXIN®
to standard dacarbazine (DTIC) chemotherapy, with or without
interferon alpha in patients, with stage IV,...





PDF





Sep 18, 2006
SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference

SAN MATEO, CA, Sep 18, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at the UBS Global Life Sciences Conference at the
Grand Hyatt New York.  Friedhelm Blobel, Ph.D., SciClone's President
and Chief Executive Officer, will deliver a corporate overview
presentat...





PDF





Sep 15, 2006
SciClone's SCV-07 Demonstrates Oral Bioavailability

SAN MATEO, CA, Sep 15, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported phase 1
data indicating that SCV-07 taken orally was safe and led to
circulating plasma concentrations similar to those obtained in
previous phase 1 studies using a subcutaneous injection of SCV-07.
Importantly, S...





PDF





Aug 1, 2006
SciClone Reports Second Quarter 2006 Results

SAN MATEO, CA, Aug 01, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the second quarter ended June 30, 2006.  For the second quarter
2006, revenues from the sale of ZADAXIN®, SciClone's lead product,
increased by 15% to $7,910,000, c...





PDF





Jul 11, 2006
SciClone to Report Second Quarter 2006 Results on August 1, 2006

SAN MATEO, CA, Jul 11, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
plans to report second quarter 2006 results and host a conference
call on Tuesday, August 1, 2006.

The conference call will contain forward-looking statements.
Financial and statistical informati...





PDF





Jun 9, 2006
SciClone Acquires Exclusive Rights in China to DC Bead Chemoembolization Device

SAN MATEO, CA, Jun 09, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it has entered into a three year agreement with Biocompatibles
International plc. (LSE: BII) granting SciClone exclusive rights to
market Biocompatibles' DC BeadTM chemotherapy releasing device within
China,...





PDF





Jun 5, 2006
SciClone Announces Presentation of Pre-Clinical Data Showing Oral SCV-07 Efficacy Against Tuberculosis

SAN MATEO, CA, Jun 05, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
presentation of pre-clinical data demonstrating that SCV-07 in an
oral formulation retains its immunomodulatory properties and is as
effective as the standard injection formulation against tuberculosis
(TB) i...





PDF





May 25, 2006
SciClone Reports Final Results From Second ZADAXIN U.S. Phase 3 Hepatitis C Trial

SAN MATEO, CA, May 25, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported final
results from its second U.S. phase 3 hepatitis C virus (HCV) trial
evaluating the benefit of adding ZADAXIN® to pegylated interferon
alpha treatment for HCV patients with...





PDF





May 3, 2006
SciClone Reports First Quarter 2006 Results

SAN MATEO, CA, May 03, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the first quarter ended March 31, 2006.  For the first quarter
2006, revenues from the sale of ZADAXIN®, SciClone's lead product,
increased by 17% to $7,789,000, co...





PDF





Apr 24, 2006
SciClone Pharmaceuticals Announces Appointment of New CEO

SAN MATEO, CA, Apr 24, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
appointment of Dr. Friedhelm Blobel as President, Chief Executive
Officer and a Director of the Company effective as of June 2, 2006.
Ira Lawrence, M.D. will continue as President and CEO until June 2,
2006, ...





PDF





Apr 21, 2006
SciClone Announces Presentation of Pre-Clinical Data Showing SCV-07 Enhances Protective Effect of Tuberculosis Vaccine

SAN MATEO, CA, Apr 21, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
presentation of data from a pre-clinical study demonstrating that the
administration of SCV-07 in conjunction with the BCG tuberculosis
(TB) vaccine resulted in a significantly superior protective effect
agai...





PDF





Apr 3, 2006
SciClone Announces Settlement of Schering Plough KK (SPKK) Dispute

SAN MATEO, CA, Apr 03, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it has reached a settlement in its dispute with SPKK concerning
clinical trials conducted in Japan with ZADAXIN®, SciClone's lead
compound.  Under this resolution, SciClo...





PDF





Mar 27, 2006
SciClone Announces Presentation of ZADAXIN Phase 2 Liver Cancer Data at Shanghai-Hong Kong International Liver Congress

SAN MATEO, CA, Mar 27, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
presentation of data from its phase 2 hepatocellular carcinoma, or
primary liver cancer, trial at the Shanghai-Hong Kong International
Liver Congress.  Dr. Robert Gish, M.D., Medical Director, Liver
Transplan...





PDF





Mar 20, 2006
SciClone's ZADAXIN Granted Orphan Drug Designation for Malignant Melanoma in United States

SAN MATEO, CA, Mar 20, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
thymalfasin, the chemical composition of ZADAXIN®, has been granted
Orphan Drug designation for the treatment of stage IIb through stage
IV malignant melanoma by the U.S....





PDF





Mar 1, 2006
SciClone Reports Results for Fourth Quarter and Year-End 2005

SAN MATEO, CA, Mar 01, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the fourth quarter and full year ended December 31, 2005.  For
the fourth quarter 2005, revenues from the sale of ZADAXIN®,
SciClone's lead product, increased by 22...





PDF





Feb 8, 2006
SciClone to Report Fourth Quarter and Year-End 2005 Results on March 1, 2006

SAN MATEO, CA, Feb 08, 2006 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it plans to report fourth quarter and year-end 2005 results and host
a conference call on Wednesday, March 1, 2006.

The conference call will contain forward-looking statements.
Financial and statist...





PDF





Dec 21, 2005
SciClone Reports Results From ZADAXIN Proof-of-Concept Liver Cancer Trial

SAN MATEO, CA, Dec 21, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today reported data from its
small, phase 2 proof-of-concept hepatocellular carcinoma (liver
cancer) trial indicating a trend toward positive survival benefit in
patients treated with ZADAXIN® plus tra...





PDF





Dec 14, 2005
SciClone Reports Results From First ZADAXIN Phase 3 Hepatitis C Trial

SAN MATEO, CA, Dec 14, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced
top-line results from the first of its two phase 3 clinical trials
using ZADAXIN® (thymalfasin) in combination with pegylated
interferon alpha to treat patients with hepatitis...





PDF





Dec 14, 2005
SciClone and Sigma-Tau Report Promising Interim Phase 2 Results in Advanced-Stage Malignant Melanoma Trial

SAN MATEO, CA, Dec 14, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A
today announced promising interim results from a large phase 2
clinical trial evaluating ZADAXIN® (thymalfasin) in combination
with dacarbazine (DTIC) chemotherapy with an...





PDF





Dec 13, 2005
SciClone to Host a Conference Call December 14, 2005 to Discuss ZADAXIN Phase 3 Hepatitis C Results and Interim Phase 2 Malignant Melanoma Data

SAN MATEO, CA, Dec 13, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it will
report ZADAXIN® phase 3 hepatitis C results and interim phase 2
malignant melanoma data before the market opens on Wednesday,
December 14, 2005 and host a conference ca...





PDF





Nov 16, 2005
SciClone Announces Data Presentations at AASLD Regarding ZADAXIN's Activity in Hepatitis B

SAN MATEO, CA, Nov 16, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced abstract
presentations of pre-clinical and clinical data from two separate
studies evaluating the activity of ZADAXIN®, also known as thymosin
alpha 1, against the hepatitis B virus...





PDF





Nov 3, 2005
SciClone to Present at Rodman and Renshaw Techvest Healthcare Conference

SAN MATEO, CA, Nov 03, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it will
present at the Rodman and Renshaw Techvest Healthcare conference at
the New York Palace Hotel in New York.  Ira D. Lawrence, M.D.,
SciClone's President and Chief Executive Officer, will deliver a
corporate...





PDF





Nov 1, 2005
SciClone Reports Third Quarter 2005 Results

SAN MATEO, CA, Nov 01, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the third quarter and nine months ended September 30, 2005.  For
the third quarter 2005, revenues from the sale of ZADAXIN®,
SciClone's lead product, were $7,016,00...





PDF





Oct 13, 2005
SciClone Pharmaceuticals to Present at Biotechnology Industry Organization (BIO) Investor Forum

SAN MATEO, CA,, Oct 13, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it will
present at the BIO Investor Forum conference at the Palace Hotel in
San Francisco.  Ira D. Lawrence, M.D., SciClone's President and Chief
Executive Officer, will deliver a corporate overview presentation o...





PDF





Oct 13, 2005
SciClone to Report Third Quarter 2005 Results on November 1, 2005

SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 13, 2005--SciClone
Pharmaceuticals, Inc. (NASDAQ:SCLN) today announced that it plans to
report third quarter 2005 results and host a conference call on
Tuesday, November 1, 2005.
    The conference call will contain forward-looking statements.
Financial and statistical information to be discussed...





PDF





Oct 10, 2005
SciClone Names Israel Rios, M.D. as Chief Medical Officer

SAN MATEO, CA, Oct 10, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced the
appointment of Israel Rios, M.D. as Chief Medical Officer. Dr. Rios
brings to SciClone over 25 years of pharmaceutical industry knowledge
and extensive experience in clinical development and the regulatory
approval...





PDF





Sep 27, 2005
SciClone to Report Top-Line Data From First U.S. Hepatitis C Phase 3 Trial by Mid-December 2005

SAN MATEO, CA, Sep 27, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it
expects to unblind and report top-line data by mid-December 2005 from
the first of its two U.S. phase 3 hepatitis C virus (HCV) clinical
trials evaluating its lead compound, ZADAXIN®...





PDF





Sep 19, 2005
SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference

SAN MATEO, CA, Sep 19, 2005 (MARKET WIRE via COMTEX News Network) -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it will
present at the UBS Global Life Sciences conference at the Grand Hyatt
New York.  Ira D. Lawrence, M.D., SciClone's President and Chief
Executive Officer, will deliver a corporate overview presentation on
T...





PDF





Aug 8, 2005
SciClone Reports Second Quarter 2005 Results

SAN MATEO, CA, Aug 08, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the second quarter and six months ended June 30, 2005.  For the
second quarter 2005, revenues from the sale of ZADAXIN®, SciClone's
lead product, reached $6,851,000, an increase...





PDF





Jul 25, 2005
SciClone Presents Preclinical Data Demonstrating SCV-07's Activity in Human Papillomavirus and Lassa Fever Models

SAN MATEO, CA, Jul 25, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
its proprietary immunomodulatory compound SCV-07 was effective in
preclinical studies, significantly reducing lesions in a model of
human papillomavirus (HPV) and increasing survival in a model of
Lassa fever.

...





PDF





Jul 13, 2005
SciClone to Report Second Quarter 2005 Results on August 8, 2005

SAN MATEO, Calif.--(BUSINESS WIRE)--July 13, 2005--SciClone
Pharmaceuticals, Inc. (NASDAQ:SCLN) today announced that it plans to
report second quarter 2005 results and host a conference call on
August 8, 2005.
    The conference call will contain forward-looking statements.
Financial and statistical information to be discussed on the ca...





PDF





Jun 23, 2005
SciClone Files IND Application for SCV-07

SAN MATEO, CA, Jun 23, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
submission of an investigational new drug (IND) application to the
U.S. Food and Drug Administration (FDA) for SCV-07, a synthetic
dipeptide that has demonstrated activity against a broad range of
viral and infectious dis...





PDF





Jun 21, 2005
SciClone Announces Zadaxin Hepatitis C Triple Therapy Poster Presentation

SAN MATEO, CA, Jun 21, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
poster presentation of additional data evaluating its lead product
candidate ZADAXIN® (thymosin alpha 1), in combination with
pegylated interferon alpha and ribavirin, as a potential t...





PDF





Jun 9, 2005
SciClone Comments on Recent Trading Activity

SAN MATEO, CA, Jun 09, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today commented that
the current market activity in its stock could be the result of an
article reporting that Sonae SGPS, SA, a Portuguese company, is
preparing to make a tender offer for SciClone.  SciClone had not been
contacted by Sonae ...





PDF





May 5, 2005
SciClone Reports First Quarter 2005 Results

SAN MATEO, CA, May 05, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the first quarter ended March 31, 2005.  For the first quarter
2005, revenues from the sale of ZADAXIN®, SciClone's lead product,
reached $6,661,000, an increase of approximatel...





PDF





Apr 28, 2005
SciClone Names Ira D. Lawrence, M.D. to Serve as President and Chief Executive Officer

SAN MATEO, CA, Apr 28, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
appointment of Ira D. Lawrence, M.D. as President, Chief Executive
Officer, and a member of the Board of Directors effective June 1,
2005.  Dr. Lawrence brings extensive international pharmaceutical
company management and...





PDF





Apr 7, 2005
SciClone to Report First Quarter 2005 Results on May 5, 2005

SAN MATEO, Calif.--(BUSINESS WIRE)--April 7, 2005--SciClone
Pharmaceuticals, Inc. (NASDAQ:SCLN) today announced that it plans to
report first quarter 2005 results and host a conference call on May 5,
2005.
    The conference call will contain forward-looking statements.
Financial and statistical information to be discussed on the call w...





PDF





Apr 4, 2005
SciClone Announces Presentation of ZADAXIN Mechanism of Action at American Association of Immunologists Conference

SAN MATEO, CA, Apr 04, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
presentation of results from a laboratory study that provides further
insight into the mechanism of action of ZADAXIN®, SciClone's lead
product candidate.  Specifically, this study rev...





PDF





Feb 23, 2005
SciClone Reports Results for Fourth Quarter and Full Year 2004

SAN MATEO, CA, Feb. 23, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results
for the fourth quarter and full year ended December 31, 2004.  For
the fourth quarter 2004, revenues from the sale of ZADAXIN,
SciClone's lead product, increased 17% to $5,985,000, compared to
$5,104,000 for the fourt...





PDF





Feb 18, 2005
SciClone Reports Management Change

SAN MATEO, CA, Feb. 18, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Eduardo B. Martins, M.D., D.Phil, Vice President of Medical Affairs,
has resigned in order to accept a position with another
biopharmaceutical company.

"On behalf of our entire company, I would like to thank Ed...





PDF





Feb 1, 2005
SciClone Announces the Appointment of Dean S. Woodman to Chairman of the Board of Directors

SAN MATEO, CA, Feb. 01, 2005 (MARKET WIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the
appointment of Dean S. Woodman to Chairman of the Board of Directors.
 Dr. Jere E. Goyan will continue as Chairman Emeritus.  Mr. Woodman
has served as a Director on SciClone's Board of Directors since
August 2000.  In a...





PDF





Jan 31, 2005
SciClone to Report Fourth Quarter 2004 Results on February 23, 2005

SAN MATEO, Calif.--(BUSINESS WIRE)--Jan. 31, 2005--SciClone
Pharmaceuticals, Inc. (NASDAQ:SCLN) today announced that it plans to
report fourth quarter and full year 2004 results and host a conference
call on February 23, 2005.
    The conference call will contain forward-looking statements.
Financial and statistical information to be di...





PDF





Dec 27, 2004
SciClone's ZADAXIN Added to Asian Pacific Consensus Recommendation for Treatment of Hepatitis B

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 27, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that its lead
product ZADAXIN® was added to the Asian Pacific consensus
recommendation for the treatment of patients infected with the
hepatitis B virus (HBV). The Asian Pacific consensus recommen...





PDF





Dec 23, 2004
SciClone's European Partner Sigma-Tau Initiates Phase 3 ZADAXIN Hepatitis C Triple Therapy Trial; First Patients Enrolled and Receiving Treatment

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 23, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that Sigma-Tau,
its European development and marketing partner for ZADAXIN®, has
begun enrolling patients infected with the hepatitis C virus (HCV) in
a multi-center European phase 3 clinical tria...





PDF





Nov 1, 2004
SciClone Reports Third Quarter Results

SAN MATEO, Calif.--(BUSINESS WIRE)--Nov. 1, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported results for the
third quarter and nine months ended September 30, 2004. Revenues from
sales of ZADAXIN®, SciClone's lead product candidate, were
$5,753,000 for the third quarter and $16,780,000 for ...





PDF





Nov 1, 2004
SciClone Announces Appointment of Richard J. Hawkins to Board of Directors

SAN MATEO, Calif.--(BUSINESS WIRE)--Nov. 1, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced the appointment of
Richard J. Hawkins to the company's Board of Directors as a
non-executive member.
    "Rick's experience in drug development, regulatory approval and
the leadership of rapidly growing pharmaceutical companies...





PDF





Nov 1, 2004
SciClone's ZADAXIN Shows Promise in Triple Therapy Trial for Hepatitis C Non-Responder Patients; Endpoint Data Presented at World's Largest Meeting of Liver Specialists

SAN MATEO, Calif.--(BUSINESS WIRE)--Nov. 1, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported that triple therapy
of ZADAXIN® combined with pegylated interferon and ribavirin in a
pilot trial in Mexico showed a sustained virologic response (SVR) in
19% of difficult to treat hepatitis C patie...





PDF





Oct 6, 2004
SciClone To Report Third Quarter 2004 Results on November 1, 2004

SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 6, 2004--SciClone
Pharmaceuticals (NASDAQ:SCLN) today announced that it expects to
report third quarter 2004 financial results on Monday, November 1,
2004 before the market opens and host a conference call and live audio
webcast at 11:30 a.m. EST that day. The conference call will include
forward-lookin...





PDF





Oct 4, 2004
SciClone Announces ZADAXIN Poster to Be Presented at AASLD

SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 4, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced the following
poster presentation on ZADAXIN® (thymosin alpha 1, thymalfasin) at
the American Association for the Study of Liver Diseases (AASLD)
meeting in Boston:
    A pilot trial of thy...





PDF





Sep 20, 2004
SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Sept. 20, 2004--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that it will present at
the UBS Global Life Sciences Conference at the Grand Hyatt in New
York. Richard A. Waldron, SciClone's Chief Financial Officer, will
deliver a corporate overview presentation on Wednesday, September 29,
2004 at 1:3...





PDF





Aug 25, 2004
Sciclone's Collaborative Partner Awarded U.S. Government Grant to Evaluate SCV-07

SAN MATEO, Calif.--(BUSINESS WIRE)--Aug. 25, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that its
collaborative partner, Verta, Ltd., has been awarded a grant from the
U.S. Government to evaluate the therapeutic potential of SCV-07 in a
hepatitis C virus (HCV) proof-of-concept trial in Russia. Based on
earlier studies sh...





PDF





Aug 4, 2004
SciClone Reports Second Quarter Results

SAN MATEO, Calif.--(BUSINESS WIRE)--Aug. 4, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported results for the
second quarter and six months ended June 30, 2004. Revenues from sales
of ZADAXIN®, SciClone's lead product candidate, were $5,613,000 for
the second quarter and $11,027,000 for the ...





PDF





Jul 19, 2004
SciClone to Report Second Quarter 2004 Results on August 4, 2004

SAN MATEO, Calif.--(BUSINESS WIRE)--July 19, 2004--SciClone
Pharmaceuticals (NASDAQ:SCLN) today announced that it expects to
report second quarter 2004 financial results on Wednesday, August 4,
2004 before the market opens and host a conference call and live audio
webcast at 11:30 a.m. EDT that day. The conference call will include
forward-loo...





PDF





Jul 14, 2004
Donald R. Sellers Resigns as President and CEO of SciClone

SAN MATEO, Calif.--(BUSINESS WIRE)--July 14, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that Don Sellers
has resigned as President and CEO of the Company after 11 years of
service. Mr. Sellers also has resigned from the Board of Directors.
However, he will continue to act as a consultant to the Company. The
Board of Dir...





PDF





Jun 15, 2004
SciClone's ZADAXIN Shows Promising Effects in Treating Brain Cancer in Animal Model Study

SAN MATEO, Calif.--(BUSINESS WIRE)--June 15, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced the results of an
animal model study evaluating its lead candidate ZADAXIN® in
combination with carmustine (BCNU), a chemotherapy agent commonly used
to treat brain tumors, as a potential therapy ...





PDF





May 26, 2004
SciClone Announces Collaboration to Develop Pegylated ZADAXIN

SAN MATEO, Calif.--(BUSINESS WIRE)--May 26, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that it has
entered into a collaborative agreement with Nektar Therapeutics'
(Nasdaq:NKTR) subsidiary, Nektar Therapeutics, AL Corporation to
develop a pegylated formulation of ZADAXIN®. Nektar wil...





PDF





May 24, 2004
SciClone Phase 3 ZADAXIN Triple Therapy Hepatitis C Trial in Europe

SAN MATEO, Calif.--(BUSINESS WIRE)--May 24, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced a multi-center
phase 3 hepatitis C triple therapy clinical trial in Europe.
SciClone's European marketing and development partner, Sigma-Tau, will
conduct this Phase 3 multicenter, double blinded study in
approximately 550 patients wi...





PDF





May 20, 2004
SciClone Achieves Enrollment Milestone for U.S. Phase 3 Hepatitis C Trials; Earns $1,000,000 Milestone Payment

SAN MATEO, Calif., May 20, 2004 (BUSINESS WIRE) -- SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that a total of
1,000 patients have been enrolled in its two U.S. phase 3 hepatitis C
(HCV) clinical trials evaluating its lead product ZADAXIN®. SciClone
has earned a $1,000,000 milestone paym...





PDF





May 14, 2004
SciClone Pharmaceuticals to Present at UBS Global Specialty Pharmaceuticals Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--May 14, 2004--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that it will present at
the UBS Global Specialty Pharmaceuticals Conference on Monday, May 24,
2004 at 9:30 a.m. EDT. Donald R. Sellers, SciClone's President and
Chief Executive Officer, will deliver a corporate overview
presentation follow...





PDF





Apr 27, 2004
SciClone Reports First Quarter Results

SAN MATEO, Calif.--(BUSINESS WIRE)--April 27, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported results for the
first quarter ended March 31, 2004. Revenues from sales of ZADAXIN®
the company's lead product, totaled $5,414,000, an 8% increase over
the $5,000,000 reported for the first quarte...





PDF





Apr 14, 2004
SciClone Explores New Combination Therapy in Hepatitis B Clinical Trial; Trial Uses High Dose of ZADAXIN in Combination with Lamivudine

SAN MATEO, Calif.--(BUSINESS WIRE)--April 14, 2004--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced an ongoing randomized
placebo-controlled clinical trial in Taiwan using a high dose of
ZADAXIN® in combination with lamivudine, the most widely used
treatment for chronic hepatitis B, to explore the po...





PDF





Apr 7, 2004
SciClone to Report First Quarter 2004 Results on April 27, 2004

SAN MATEO, Calif.--(BUSINESS WIRE)--April 7, 2004--SciClone
Pharmaceuticals (NASDAQ: SCLN), today announced that it expects to
report first quarter 2004 financial results on Tuesday, April 27, 2004
before the market opens and host a conference call and live audio
webcast at 2:00 p.m. EDT that day. The conference call will include
forward-looki...





PDF





Mar 1, 2004
SciClone's ZADAXIN Demonstrates Significant Anti-Fungal Efficacy in Invasive Aspergillosis Animal Study

SAN MATEO, Calif.--(BUSINESS WIRE)--March 1, 2004--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced the publication of
results from a new animal model study demonstrating, for the first
time, that its lead drug candidate ZADAXIN® is an effective
anti-fungal treatment for invasive aspergillosis. The st...





PDF





Feb 24, 2004
SciClone Reports Results for Fourth Quarter and Full Year 2003

SAN MATEO, Calif.--(BUSINESS WIRE)--Feb. 24, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported results for the
fourth quarter and full year ended December 31, 2003. Revenues from
sales of ZADAXIN®, the company's lead immune system enhancer drug,
were $5,104,000 for the fourth quarter of 2003...





PDF





Feb 18, 2004
SciClone Reports Data: 41% of Hepatitis C Non-Responder Patients Test HCV RNA Negative after 24 Weeks of ZADAXIN Triple Therapy

SAN MATEO, Calif.--(BUSINESS WIRE)--Feb. 18, 2004--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN)
    --  Pilot Trial Treating Patients Not Responding to Prior Therapy
        Continues to Show Positive Results
    SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported
positive data from a pilot clinical trial in hepati...





PDF





Feb 2, 2004
SciClone to Report Fourth Quarter 2003 Results on February 24, 2004

SAN MATEO, Calif.--(BUSINESS WIRE)--Feb. 2, 2004--SciClone
Pharmaceuticals (NASDAQ:SCLN), today announced that it expects to
report fourth quarter 2003 results on Tuesday, February 24, 2004
before the market opens and host a conference call and live audio
webcast at 2:00 p.m. EST that day. The conference call will include
forward-looking state...





PDF





Dec 8, 2003
SciClone Pharmaceuticals To Present at Harris Nesbitt Gerard Healthcare Conference

 SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 8, 2003--SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it will present at the Harris Nesbitt Gerard Healthcare Conference on Thursday, December 11, 2003 at 11:45 am EST. Donald R. Sellers, SciClone's President and Chief Executive Officer, will deliver a corporate overview presentation. The pr...





PDF





Oct 27, 2003
SciClone's ZADAXIN in Triple Therapy Shows 61% Early Virologic Response for Hepatitis C Non-Responders; 12-Week Data Presented at World's Largest Meeting of Liver Specialists

SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 27, 2003--SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported positive data from
a triple therapy pilot study showing ZADAXIN® in combination with
pegylated interferon alpha and ribavirin produced a 12-week early
virologic response (EVR) in 61% of hepatitis ...





PDF





Oct 27, 2003
SciClone Reports Third Quarter Results; Sales of ZADAXIN Increase 26% to $5.4 Million

SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 27, 2003--SciClone
Pharmaceuticals, Inc. (NASDAQ:SCLN) today reported results for the
third quarter ended September 30, 2003. Revenues from sales of
ZADAXIN®, the company's lead immune system enhancer drug, were
$5,421,000 for the third quarter of 2003, a 26% increas...





PDF





Oct 13, 2003
SciClone to Report Third Quarter 2003 Results on October 27, 2003

SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 13, 2003--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that it expects to
report third quarter 2003 results on Monday, October 27, 2003 before
the market opens and host a conference call and live audio webcast at
2:30 p.m. EST (11:30 a.m. PST) on the same day. The conference call
will include ...





PDF





Oct 7, 2003
SciClone Receives U.S. Government Grant to Develop Oral Formulation of SCV-07; Grant Also Funds Additional Phase 2 Tuberculosis Clinical Trials in Russia

SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 7, 2003--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that it has received a
grant from the U.S. Government to develop an oral formulation for
SCV-07, SciClone's proprietary compound that enhances the immune
system. In previous phase 2 clinical trials, SCV-07 formulated as an
injectable produc...





PDF





Oct 2, 2003
SciClone Announces ZADAXIN Poster to Be Presented At AASLD

SAN MATEO, Calif.--(BUSINESS WIRE)--Oct. 2, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced the following
poster presentation on ZADAXIN® (thymosin alpha 1, thymalfasin) at
The American Association for the Study of Liver Diseases (AASLD)
meeting in Boston:
    A pilot trial of thy...





PDF





Sep 24, 2003
SciClone Completes Enrollment of 500 Patients in First of Two Phase 3 Hepatitis C Trials

SAN MATEO, Calif.--(BUSINESS WIRE)--Sept. 24, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) announced today that it has
completed the planned enrollment of 500 patients in the first of its
two phase 3 hepatitis C (HCV) clinical trials evaluating its lead
immune system enhancing drug ZADAXIN. SciClone intends to complete
enrollment of the ...





PDF





Sep 18, 2003
SciClone Announces Offering of 6,000,000 Shares of Common Stock

SAN MATEO, Calif., Sep 18, 2003 (BUSINESS WIRE) -- SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) announced that it commenced today
the public offering of 6,000,000 shares of its common stock. All
shares are being offered by SciClone. In addition, the underwriters
have a 30-day period in which to exercise an option to purchase up to
900,000 a...





PDF





Jul 31, 2003
SciClone Announces Filing of Registration Statement for Public Offering of Common Stock

SAN MATEO, Calif.--(BUSINESS WIRE)--July 31, 2003--SciClone
Pharmaceuticals, Inc. (the Company) (Nasdaq:SCLN) announced today that
it has filed a registration statement with the Securities and Exchange
Commission for the public offering of 6,000,000 shares of its common
stock. All shares will be offered by the Company. In addition, the
underwr...





PDF





Jul 28, 2003
SciClone Reports Second Quarter Results; Record ZADAXIN Sales of $16.2 Million and Net Income of $5.1 Million

SAN MATEO, Calif., Jul 28, 2003 (BUSINESS WIRE) -- SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported net income of
$5,124,000, or $0.13 per fully diluted share, for the second quarter
ended June 30, 2003. Revenues from sales of ZADAXIN®, the company's
lead immune system enhancer drug, reached a...





PDF





Jul 28, 2003
SciClone Announces Completion of Reincorporation and Termination of Rights Agreement

SAN MATEO, Calif.--(BUSINESS WIRE)--July 28, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that it has
completed its previously announced reincorporation from the State of
California to the State of Delaware. In connection with the
reincorporation, SciClone terminated its shareholder rights agreement.
    As previou...





PDF





Jul 18, 2003
SciClone to Report Second Quarter 2003 Results on July 28, 2003

SAN MATEO, Calif.--(BUSINESS WIRE)--July 18, 2003--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that it expects to
report second quarter 2003 results on Monday, July 28, 2003 before the
market opens and host a conference call and live audio webcast at 1:00
pm EDT (10:00 am PDT) on the same day. The conference call will
include forwar...





PDF





Jul 3, 2003
SciClone Sponsors ZADAXIN Symposium at International Conference for the Study of the Liver; Panel of Experts Discuss ZADAXIN as a Treatment for Hepatitis C and B

SAN MATEO, Calif.--(BUSINESS WIRE)--July 3, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) announced that it is sponsoring a
satellite symposium today at the European Association for the Study of
the Liver (EASL) in Geneva, Switzerland. At the symposium,
internationally renowned experts in immunology and liver disease plan
to discuss ZADAX...





PDF





Jun 25, 2003
SciClone's Shareholders Approve Reincorporation in Delaware

SAN MATEO, Calif.--(BUSINESS WIRE)--June 25, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that shareholders
voted in favor of the 2003 proxy proposals to reincorporate in the
State of Delaware and each of the additional charter revisions.
Shareholders also voted to reelect all seven Directors, to approve
Ernst & Young...





PDF





Jun 25, 2003
SciClone Announces Positive Data from Phase 3 Hepatitis B Trial in Japan; Begins Japanese New Drug Application Process

SAN MATEO, Calif.--(BUSINESS WIRE)--June 25, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) at its Annual Meeting of
Shareholders today announced positive data from its phase 3 clinical
trial in Japan using its lead immune system enhancing drug ZADAXIN as
a treatment for hepatitis B. Efficacy measurements showed that 27% of
patients had ne...





PDF





Jun 20, 2003
Study Demonstrates Mechanism of Action for SciClone's SCV-07 in Treating Tuberculosis

SAN MATEO, Calif.--(BUSINESS WIRE)--June 20, 2003--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced the results of a
tuberculosis (TB) animal model study demonstrating the mechanism of
action of SCV-07, the Company's proprietary compound that enhances the
immune system. The study showed that SCV-07 stimulated a Th1 immune
response, which...





PDF





Jun 16, 2003
SciClone Selected for Russell 3000 Index

SAN MATEO, Calif.--(BUSINESS WIRE)--June 16, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that it has been
selected to be added to the Russell 3000® Index. As part of
Russell's annual reconstitution of its equity indexes, additions will
take place on Tuesday, July 1, 2003 and will rema...





PDF





May 29, 2003
SciClone's Largest Shareholders Support Proxy Proposals

SAN MATEO, Calif.--(BUSINESS WIRE)--May 29, 2003--SciClone
Pharmaceuticals today announced that its two largest shareholders
Sigma-Tau and Randal J. Kirk have advised SciClone that they intend to
vote in favor of the proposed reincorporation in the state of Delaware
and certain additional charter revisions to be considered at the June
25, 2003...





PDF





May 28, 2003
SciClone Pharmaceuticals to Present at UBS Warburg's Global Specialty Pharmaceuticals Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--May 28, 2003--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that it will present at
UBS Warburg's Global Specialty Pharmaceuticals Conference on Thursday,
June 5, 2002 at 1:00 pm EDT. Donald R. Sellers, SciClone's President
and Chief Executive Officer, will deliver a corporate overview
presentation ...





PDF





May 28, 2003
CBOE To List Options on SciClone Common Stock

SAN MATEO, Calif., May 28, 2003 (BUSINESS WIRE) -- SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that the Chicago Board
Options Exchange (CBOE) will list options under the ticker symbol SUV
on SciClone common stock beginning Thursday, May 29, 2003. For more
information on new listings, visit the Trading Tools section of the
CBOE we...





PDF





May 12, 2003
SciClone Added to NASDAQ Biotech Index

SAN MATEO, Calif.--(BUSINESS WIRE)--May 12, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that it has been
selected to be added to the NASDAQ Biotechnology Index (NBI) effective
Monday, May 19, 2003. All securities in the Index are listed on the
NASDAQ National Market and meet minimum requirements including market
value, a...





PDF





May 6, 2003
SARS Related ZADAXIN Sales to China Expected to Increase Second Quarter Revenue to over $15 Million

SAN MATEO, Calif.--(BUSINESS WIRE)--May 6, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that SARS related
export sales to China are expected to drive sales of ZADAXIN®, the
Company's lead immune system enhancing drug, to more than $15 million
for the second quarter of 2003. This compar...





PDF





Apr 24, 2003
SciClone Reports First Quarter Results; Record ZADAXIN Sales for First Quarter 2003

SAN MATEO, Calif.--(BUSINESS WIRE)--April 24, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported results for the
first quarter ended March 31, 2003. Revenues from sales of ZADAXIN®,
the company's lead immune system enhancer drug, reached a record
$5,000,000, a 27% increase over the $3,948,000...





PDF





Apr 14, 2003
SciClone to Report First Quarter 2003 Results on April 24, 2003

SAN MATEO, Calif., Apr 14, 2003 (BUSINESS WIRE) -- SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that it expects to
report first quarter 2003 results on Thursday, April 24, 2003 before
the market opens and host a conference call and live audio webcast at
2:00 pm EST (11:00 am PST) on the same day. The conference call will
include f...





PDF





Apr 9, 2003
ZADAXIN Combination Therapy Shows 71% Sustained Response in Hepatitis B Patients

SAN MATEO, Calif., Apr 9, 2003 (BUSINESS WIRE) -- SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced the results of a study
showing a 71% long-term sustained response rate for difficult to treat
hepatitis B patients. These results were achieved after only one year
of combination therapy with ZADAXIN and interferon alpha. This
sustained ...





PDF





Feb 24, 2003
SciClone Pharmaceuticals to Present at RedChip Investor Conference in Boston

SAN MATEO, Calif., Feb 24, 2003 (BUSINESS WIRE) -- SciClone Pharmaceuticals,
Inc. (Nasdaq:SCLN), a biopharmaceutical company engaged in the development of
therapeutics to treat life-threatening diseases, announced that it will present
at RedChip Partners Investor Conference in Boston on Wednesday, February 26,
2003 at 8:30 am (Eastern Standard ...





PDF





Feb 4, 2003
SciClone Reports Record ZADAXIN Sales for Fourth Quarter and Full Year 2002; Phase 3 Hepatitis B Clinical Trial in Japan Completed on Schedule

SAN MATEO, Calif., Feb 4, 2003 (BUSINESS WIRE) -- SciClone Pharmaceuticals,
Inc. (Nasdaq:SCLN) today reported results for the fourth quarter ended December
31, 2002. Revenues from sales of ZADAXIN®, the company's lead immune system
enhancer drug, reached a record $4,807,000, a 24% increase over the $3,888,00...





PDF





Jan 23, 2003
Sigma-Tau Increases Equity Position in SciClone; Sigma-Tau Group Invests Additional $1.8 Million in SciClone

SAN MATEO, Calif.--(BUSINESS WIRE)--Jan. 23, 2003--SciClone
Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that Sigma-Tau
and its affiliates increased their aggregate ownership to close to 10%
of SciClone's common stock outstanding by purchasing approximately
505,000 unregistered shares of common stock directly from the company
for $1.8 m...





PDF





Jan 13, 2003
SciClone to Report 2002 Results February 4, 2003; Japanese Phase 3 Hepatitis B Trial Completed on Schedule

SAN MATEO, Calif.--(BUSINESS WIRE)--Jan. 13, 2003--SciClone
Pharmaceuticals (Nasdaq:SCLN) today announced that it expects to
report fourth quarter and fiscal year 2002 results on Tuesday, Feb. 4,
2003 before the market opens and host a conference call and live audio
webcast at 1:00 p.m. EST (10:00 a.m. PST) on the same day. The
conference call...





PDF





Dec 9, 2002
SciClone Pharmaceuticals To Present at CCBN's Virtual Healthcare Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 9, 2002--SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), will present at CCBN's Virtual Healthcare Conference on Tuesday, December 10, 2002 at 4:15 pm EST (1:15 pm PST). Donald R. Sellers, SciClone's President and Chief Executive Officer, will deliver a corporate overview presentation which will be webcast li...





PDF





Nov 18, 2002
SciClone Pharmaceuticals To Present At RedChip Investor Conference in Phoenix

BIOWIRE2K 
SAN MATEO, Calif.--(BUSINESS WIRE)--Nov. 18, 2002--SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN), a biopharmaceutical company primarily focused on the development of Immune System Enhancers (ISEs) for the treatment of infectious diseases and cancer, announced that it will present at RedChip Partners Investor Conference in Phoenix on Satu...





PDF





Nov 11, 2002
ZADAXIN Significantly Increases Survival in Melanoma Animal Study; Study Presented at American Society of Clinical Oncologists --ASCO-- Meeting

BIOWIRE2K SAN MATEO, Calif.--(BUSINESS WIRE)--Nov. 11, 2002--SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported results from a new animal model study demonstrating that ZADAXIN treatment following standard chemotherapy for melanoma significantly increases survival. In the study, 60% of the group treated with ZADAXIN via continu...





PDF





Nov 4, 2002
SciClone Pharmaceuticals Reports Third Quarter 2002 Results; New Data Support Clinical Trials; ZADAXIN Sales up 20%

SAN MATEO, Calif., Nov 4, 2002 (BUSINESS WIRE) -- SciClone Pharmaceuticals,
Inc. (Nasdaq:SCLN) today reported results from the third quarter ended September
30, 2002. Revenues from sales of ZADAXIN, the company's lead immune system
enhancer drug, were $4,298,000, a 20% increase over the $3,580,000 reported
during the third quarter of 2001. In a...





PDF





Nov 4, 2002
ZADAXIN Adds Benefit to Pegylated Interferon for HCV Non-Responders; Hepatitis C Patients Who Failed Prior Therapy Responding to ZADAXIN

SAN MATEO, Calif., Nov 4, 2002 (BUSINESS WIRE) -- ZADAXIN® in combination with pegylated interferon advanced in its effort to be part of the first approved hepatitis C therapy for non-responders. Close to half of all patients fail to respond to initial treatment with currently available therapies and become non...





PDF





Oct 31, 2002
ZADAXIN Shows Direct Antiviral Effects On Cells Infected With Hepatitis B and HIV

SAN MATEO, Calif., Oct 31, 2002 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) today reported that ZADAXIN®, in addition to previously observed immunological effects, for the first time has shown direct antiviral effects on cells infected with the hepatitis B virus (HBV) and human immunodeficie...





PDF





Oct 23, 2002
SciClone Pharmaceuticals to Release Third Quarter 2002 Results On November 4, 2002; Conference Call and Webcast Scheduled

SAN MATEO, Calif., Oct 23, 2002 (BUSINESS WIRE) -- SciClone Pharmaceuticals (Nasdaq:SCLN) announced that its third quarter 2002 results will be released on Monday, November 4, 2002 before the market opens. A conference call and live webcast have been scheduled for 3:00 pm EST (12:00 am PST). Donald Sellers, President and Chief Executive Officer, Ri...





PDF





Sep 28, 2002
SciClone's Innovative SCV-07 Immune System Therapy Yields Positive Clinical Results in Tuberculosis

Data from Phase 2 Clinical Trials Presented at ICAAC
SAN MATEO, Calif., Sep 28, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) today reported that SCV-07, a proprietary compound that enhances the immune system, demonstrated the capability to significantly increase the rate at which tr...





PDF





Sep 17, 2002
SciClone Pharmaceuticals To Present at Bear Stearns' Healthcare Conference Tuesday, September 17, 2002, at 7:00 am ET

SAN MATEO, Calif., Sep 17, 2002 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) will present at the Bear Stearns' 15th Annual Healthcare Conference today at 9:30 a.m. Eastern Time. Donald R. Sellers, SciClone's President and Chief Executive Officer, will deliver a presentation which will be webcast live by accessing www.sciclone.co...





PDF





Sep 12, 2002
ZADAXIN Improves Immune System's Detection of Colorectal Cancer Cells

ZADAXIN Enhances Potential for Both Therapy and DiagnosisSAN MATEO, Calif., Sep 12, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) today reported that treating colorectal cancer cells with ZADAXIN® significantly increases the expression of a detect...





PDF





Sep 9, 2002
SciClone's ZADAXIN in Phase 2 Cancer Clinical Trial in Europe

- Major Phase 2-3 Cancer Program Targets Malignant Melanoma -
SAN MATEO, Calif., Sep 9, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced today that its European Union marketing and development partner, Sigma-Tau S.p.A., has started a large phase 2 clinical trial in Europe usin...





PDF





Sep 5, 2002
SciClone Pharmaceuticals, Inc. To Present At RedChip Partners Investor Conference in New York - Sept. 19, 2002; Steve Forbes, Editor-in-Chief of Forbes Magazine, To Speak

SAN MATEO, Calif., Sep 5, 2002 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), a biopharmaceutical company whose lead product ZADAXIN is in phase 3 hepatitis C trials in the U.S., a phase 3 hepatitis B trial in Japan and a phase 2-3 cancer program in Europe, will present at the RedChip Partners...





PDF





Sep 4, 2002
SciClone to Present at Bear Stearns and RedChip New York Conferences

SAN MATEO, Calif., Sep 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced that it will present at Bear Stearns' 15th Annual Healthcare Conference on Tuesday, September 17, 2002 at 9:30 am (Eastern Daylight Time) and at RedChip Partners Investor Conference on T...





PDF





Aug 6, 2002
SciClone Pharmaceuticals Reports Second Quarter 2002 Results

SAN MATEO, Calif., Aug 6, 2002 /PRNewswire-FirstCall via COMTEX/ --25% Increase in ZADAXIN® Revenues SciClone
Pharmaceuticals, Inc. (Nasdaq: SCLN) today reported results from the second
quarter ended June 30, 2002. Revenues from sales of ZADAXIN, the company's lead
immune system enhancer...





PDF





Jul 26, 2002
SciClone Pharmaceuticals to Release Second Quarter 2002 Results On August 6, 2002

Conference Call and Webcast Scheduled
SAN MATEO, Calif., Jul 26, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals (Nasdaq: SCLN) announced that its second quarter 2002 results will be released on Tuesday, August 6, 2002 before the market opens. A conference call and live webcast have been scheduled for 1:00 pm Eastern ...





PDF





Jul 16, 2002
ZADAXIN Produces Sustained Responses in Most Difficult to Treat Hepatitis B Patients

SAN MATEO, Calif., Jul 16, 2002 /PRNewswire-FirstCall via COMTEX/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced the results of a new study demonstrating that ZADAXIN® (thymalfasin, thymosin alpha 1) helps clear the hepatitis B virus in the most difficult to treat patients, those in the immune toler...





PDF





Jul 9, 2002
ZADAXIN Increases Breast Cancer Survival Rate in NIH Animal Model

SAN MATEO, Calif., Jul 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the positive results of a breast cancer animal model study using monotherapy ZADAXIN®® as an immune system enhancer. At the 21-week endpoint of the st...





PDF





Jun 14, 2002
SciClone Pharmaceuticals Completes Direct Offering of Common Stock

Various Existing and New Institutional Investors ParticipateSAN MATEO, Calif., Jun 14, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) today announced that it completed a direct offering of common stock with various existing and new institutional investors. SciClone raised gross proceed...





PDF





Jun 7, 2002
SciClone Pharmaceuticals Announces Direct Offering of Common Stock

SAN MATEO, Calif., Jun 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- 
SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) today announced that it has priced its direct offering of 4,088,460 shares of its common stock at $2.60 per share. The shares were offered to various institutional investors under SciClone's shelf registration statement that was initi...





PDF





Jun 6, 2002
SciClone Pharmaceuticals Presents at UBS Warburg's Global Specialty Pharmaceuticals Conference

SAN MATEO, Calif., Jun 6, 2002 /PRNewswire-FirstCall via COMTEX/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced that it will present at UBS Warburg's Global Specialty Pharmaceuticals Conference today, June 6, 2002 at 10:30 am (Eastern Daylight Time). Donald R. Sellers, SciClone's President and Chief Executive Officer, will deliver a cor...





PDF





May 30, 2002
SciClone Pharmaceuticals Announces Result of 2002 Proxy Vote

SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) today announced the results of its 2002 proxy vote. SAN MATEO, Calif., May 30, 2002 /PRNewsire-FirstCall via Comtex/ -- The company is holding its 2002 Annual Meeting of Shareholders at 1:00 pm EDT (10:00 am PDT) and a presentation and following Q&A will be webcast at 1:30 pm EDT (10:30 am PDT). The web...





PDF





May 22, 2002
ZADAXIN® Selectively Stimulates Immune System-Related Genes Important In the Fight Against Hepatitis C

Study Presented at the AASLD's Digestive Disease WeekSAN MATEO, Calif., May 22, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced the results of a study demonstrating that ZADAXIN (thymalfasin, thymosin alpha 1) upregulates the expression of multiple immune system-related genes ...





PDF





May 15, 2002
SciClone Pharmaceuticals to Webcast Presentation and Following Q&A After Annual Meeting on May 30, 2002

SciClone Pharmaceuticals to Webcast Presentation and Following Q&A After Annual Meeting on May 30, 2002 
SAN MATEO, Calif., May 15, 2002 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced that it will webcast a presentation and Q&A after the 2002 Annual Meeting of Shareholders. The Annual Meeting will be at the Hilton Garde...





PDF





May 8, 2002
SciClone Pharmaceuticals Reports First Quarter 2002 Results

27% Increase in ZADAXIN® Revenues


    SAN MATEO, Calif., May 8 /PRNewswire-FirstCall/ --
SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) today reported results from the
first quarter ended March 31, 2002.  Revenues from sales of ZADAXIN, the
company's lead immune system enhancer drug, were $3,948,0...





PDF





Apr 16, 2002
SciClone Sponsors First ZADAXIN® Symposium at International Conference For the Study of the Liver

Panel of Experts Discuss ZADAXIN as a Treatment for Hepatitis BSAN MATEO, Calif., Apr 16, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) sponsored a satellite symposium yesterday on the opening day of the joint meetings of the International Association for the Study of the Liver (IASL)...





PDF





Apr 15, 2002
SciClone Begins ZADAXIN® U.S Phase 3 Hepatitis C Clinical Trials

First Patients Enrolled and Receiving TreatmentSAN MATEO, Calif., Apr 15, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the first patients in its ZADAXIN U.S. phase 3 hepatitis C clinical trials have been enrolled and are receiving treatment. "The injection of the first pati...





PDF





Apr 9, 2002
ZADAXIN® Offers New Cancer Treatment Benefits

ZADAXIN Leads to Bone Marrow Recovery After Chemotherapy Study Presented at the American Association for Cancer Research Annual MeetingSAN MATEO, Calif., Apr 9, 2002 /PRNewswire-FirstCall via COMTEX/ --SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the results of an animal model study demonstrating improved and expa...





PDF





Mar 19, 2002
Study Shows New Data Supporting ZADAXIN's Ability to Increase Th1 Subset Of T-Helper Cells

SAN MATEO, Calif., Mar 19, 2002 /PRNewswire-FirstCall via COMTEX/ --Data Presented at World Congress of Gastroenterology
SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the results of a nonclinical study supporting ZADAXIN's observed mechanism of action. The study was presented this month at the World Congress of Gastroenterology in Bangko...





PDF





Mar 13, 2002
ZADAXIN in Combination Therapy Has Significantly Superior Sustained Response Rates Compared to Interferon Monotherapy for Hepatitis B

SAN MATEO, Calif., Mar 13, 2002 /PRNewswire-FirstCall via COMTEX/ --71% for ZADAXIN in Combination Therapy Versus 10% for Interferon MonotherapySciClone Pharmaceuticals (Nasdaq: SCLN) today announced that data presented at the World Congress of Gastroenterology in Bangkok, Thailand this month indicate that, after an addition...





PDF





Mar 5, 2002
SciClone Pharmaceuticals Announces Positive Preliminary Data From Phase 3 Hepatitis B Trial in Japan

SAN MATEO, Calif., Mar 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced positive preliminary data from its phase 3 clinical trial in Japan using ZADAXIN as a monotherapy treatment for hepatitis B. Preliminary data on approximately one-third of the 319 patients indicate that, after 6 months of ther...





PDF





Feb 22, 2002
SciClone Pharmaceuticals, Inc. to Present At RedChip Partners Investor Conference in Boca Raton, Fla. On March 7

SAN MATEO, Calif., Feb 22, 2002 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN), a global biopharmaceutical company that acquires, develops and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases, will present at the RedChip Partners Investor Conference ...





PDF





Feb 7, 2002
SciClone Pharmaceuticals Reports Fourth Quarter and Year End 2001 Results

SAN MATEO, Calif., Feb 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- SciClone
Pharmaceuticals (Nasdaq: SCLN) today reported that total revenues for the fourth
quarter ended December 31, 2001 from sales of ZADAXIN®, our lead immune system
enhancer drug, increased 31% to $3,888,000 compared to $2,977,000 for th...





PDF





Dec 20, 2001
ZADAXIN Enters European Phase 2-3 Cancer Program

SAN MATEO, Calif., Dec 20, 2001 /PRNewswire via COMTEX/ --SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the initiation of a late-stage oncology clinical development program in Europe for ZADAXIN, SciClone's lead immune system enhancer drug. The clinical program is being sponsored by Sigma-Tau S.p.A., SciClone's exclusive partner for ZADAX...





PDF





Sep 20, 2001
SciClone Named One of Silicon Valley's Fastest Growing Technology Companies in Deloitte & Touche's Fast 50 Program

SAN MATEO, Calif., Sep 20, 2001 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company has been named as a part of Deloitte & Touche's prestigious "2001 Technology Fast 50" Program for Silicon Valley, a ranking of the 50 fastest growing technology companies in the area. Rankings are based on the percentage of growt...





PDF





Sep 4, 2001
SciClone Pharmaceuticals Inc. To Present at RedChip Investor Conference in New York Tuesday, Sept. 11, 2001, at 8 a.m. ET `7 a.m. CT'

NEW YORK--(BUSINESS WIRE)--Sept. 4, 2001--SciClone Pharmaceuticals Inc. (Nasdaq:SCLN), a company engaged in drug development and commercialization, will present at the RedChip investor conference in New York on Tuesday, Sept. 11, 2001. The conference will be held at the Waldorf-Astoria Hotel, 301 Park Ave., b...





PDF





Aug 28, 2001
SciClone Receives Hepatitis C Patent Allowance in Japan

SAN MATEO, Calif., Aug. 28 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company has received a Notice of Allowance for patent protection in Japan covering the use of ZADAXIN, the Company's lead immune system enhancer (ISE) drug, for the treatment of hepatitis C. The new patent, which extends through 2012, also co...





PDF





Aug 22, 2001
SciClone Completes Enrollment for ZADAXIN® Phase 3 Hepatitis B Trial In Japan

SAN MATEO, Calif., Aug 22, 2001 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company has completed enrollment for its phase 3 monotherapy hepatitis B trial in Japan, the second largest pharmaceutical market in the world, with ZADAXIN®, the Company's lead immune system enhance...





PDF





Jul 24, 2001
SciClone Pharmaceuticals Receives U.S. Patent Allowance for the Use Of Zadaxin® Plus Lamivudine and Famciclovir to Treat Hepatitis B

SAN MATEO, Calif., Jul 24, 2001 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for use of the Company's lead drug, ZADAXIN® plus lamivudine and famciclovir for the treatment of hepatitis B. ZADAXIN is an immune s...





PDF





Jul 23, 2001
SciClone's ZADAXIN® Approved as Cancer Treatment in the Philippines

SAN MATEO, Calif., Jul 23, 2001 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that ZADAXIN®, the Company's lead immune system enhancer (ISE) drug, has been approved in The Philippines as an adjuvant to chemotherapy for the treatment of various cancers. ZADAXIN previously was approved i...





PDF





Jul 10, 2001
SciClone's ZADAXIN® Approval Expanded to Include Hepatitis C and Hepatitis B In Mexico

SAN MATEO, Calif., Jul 10, 2001 /PRNewswire/ --SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company's immune system enhancer, ZADAXIN® has received expanded indications in Mexico. ZADAXIN may now be marketed for the treatment of hepatitis C and hepatitis B as well as for use as an influenza ...





PDF





Jun 18, 2001
SciClone Pharmaceuticals Inc. To Present at RedChip Investor Conference Thursday, June 21, 2001, at 5:30 p.m. ET - 2:30 p.m. PT

PORTLAND, Ore.--(BUSINESS WIRE)--June 18, 2001--SciClone Pharmaceuticals Inc. (Nasdaq:SCLN), a developer of drugs for chronic diseases, will present at the RedChip™ Investor Conference in Portland, Ore., on Thursday, June 21, 2001, at 5:30 p.m. Eastern Time (2:30 p.m. Pacific Time). This event is b...





PDF





May 29, 2001
SciClone Pharmaceuticals to Offer Webcast of Presentation and Q&A Following Annual Meeting On Thursday, May 31, 2001

SAN MATEO, Calif.--(BUSINESS WIRE)--May 29, 2001--SciClone Pharmaceuticals (Nasdaq:SCLN) today announced that it will webcast the annual presentation and Q&A following the 2001 Annual Meeting of Stockholders on Thursday, May 31, at 10:30 a.m. Pacific Time. The meeting will be held at the Hilton Garden Inn, at 2000 Bridgepointe Circle, San Mateo, Ca...





PDF





Mar 19, 2001
SciClone Appoints Richard A. Waldron as Chief Financial Officer

San Mateo, CA, March 19, 2001 - SciClone Pharmaceuticals (Nasdaq: SCLN) today named Richard A. Waldron as Chief Financial Officer. In addition to his responsibilities as Chief Financial Officer, Mr. Waldron will also be extensively involved in corporate development and serve as a member of SciClone's executive staff.
"SciClone Pharmaceuticals h...





PDF





Feb 20, 2001
SciClone's ZADAXIN® is Able to Increase Anti-Tumor Effects, While Markedly Reducing the Toxicity of Chemotherapy, in Treating Melanoma, Colorectal Cancer, and NSCLC

San Mateo, CA, February 20, 2001 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced at the Roth Capital Partners 13th Annual Growth Stock Conference that a review published in the peer-reviewed journal International Journal of Immunopharmacology (Volume 22, pp. 1067-1076) discusses that ZADAXIN®, SciClone...





PDF





Feb 15, 2001
SciClone Pharmaceuticals Reports 2000 Results

San Mateo, CA, February 15, 2001 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced results for the fourth quarter and year ended December 31, 2000.
For the year ended December 31, 2000, SciClone reported total revenues increased 63% to $15,357,000, based entirely on sales of ZADAXIN®...





PDF





Feb 5, 2001
SciClone's ZADAXIN® approved in India for Hepatitis B

San Mateo, CA, February 5, 2001 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that its lead drug, ZADAXIN®, has been approved in India for the treatment of hepatitis B. SciClone reported that commercial introduction of ZADAXIN into the Indian market could begin as early as the second quarter of this y...





PDF





Jan 10, 2001
SciClone Pharmaceuticals Starts  Pivotal U.S. Phase 3 Hepatitis C Program with Zadaxin Plus Pegylated Alfa Interferon

San Mateo, CA, January 10, 2001 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that it has initiated its pivotal U.S. Phase 3
                      hepatitis C clinical program for ZADAXIN® in combination with Pegasys® pegylated interferon alfa-2a. SciClone's pivotal phase 3 hepatitis C
                      program, its larges...





PDF





Jan 8, 2001
SciClone Initiates U.S. Phase 2 Liver Cancer Trial With Zadaxin® Plus Radio Frequency Ablation

San Mateo, CA, January 8, 2001 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the initiation of a U.S. Phase 2 study in
                      patients with hepatocellular carcinoma, evaluating the effectiveness of ZADAXIN®, the Company's immune system enhancer, in combi...





PDF





Jan 2, 2001
SciClone Named One of 10 Best Health Care Websites

San Mateo, CA, January 2, 2001 - SciClone Pharmaceuticals (Nasdaq: SCLN) said its website - www.sciclone.com - has been named one of the
                      10 best sites in the health care industry by Med Ad News, a leading trade publication for healthcare marketing and advertising professionals.
                      SciClone was chosen as on...





PDF





Dec 19, 2000
SciClone Pharmaceuticals Completes $4.9 Million Financing

San Mateo, CA, December 19, 2000 -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) today announced the purchase by an investment
                      affiliate of UBS AG, one of the world's five largest financial institutions, of a $4 million senior unsecured convertible note. SciClone also
                      received $900,000 for the right to...





PDF





Dec 6, 2000
SciClone Pharmaceuticals Receives Second European Patent for the Treatment of Hepatitis C with Zadaxin®

San Mateo, CA, December 6, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the European Patent Office has
                      allowed the Company a patent covering the use of ZADAXIN® for the treatment of hepatitis C in non-responders. A non-responder is a
...





PDF





Dec 4, 2000
SciClone Comments On Product Revenue Expectations


San Mateo, CA, December 4, 2000 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced updated expectations for product revenues in the fourth quarter of 2000.  The Company now expects that product sales for the fourth quarter of 2000 will fall below those of the year's third quar...





PDF





Nov 20, 2000
SciClone Pharmaceuticals Initiates Zadaxin® Malignant Melanoma Clinical Study in Australia

San Mateo, CA, November 20, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced that a new ZADAXIN® clinical study for malignant
                      melanoma, the deadliest form of skin cancer and one of the most rapidly increasing types of cancer worldwide, has been initiated in Australia.           ...





PDF





Nov 16, 2000
SciClone Pharmaceuticals Named One of the 500 Fastest Growing Technology Companies in North America

San Mateo, CA, November 16, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company has been recognized
                      as part of the Deloitte & Touche "Technology Fast 500" award in year 2000 for the 500 fastest growing technology companies in the U.S. and
                      Canada. Rankings are based on five-y...





PDF





Nov 10, 2000
SciClone Pharmaceuticals Announces Successful Reformulation of CPX for Expanded Phase 2 Studies in Cystic Fibrosis Patients

San Mateo, CA, November 10, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced at the Cystic Fibrosis Foundation's (CFF)
                      14th Annual North American Cystic Fibrosis Conference in Baltimore that CPX, the Company's lead protein-repair therapy for cystic fibrosis
                      (CF), has been successfully ref...





PDF





Nov 3, 2000
SciClone Pharmaceuticals Receives 2000 "New Product/ Technology Development" Award from City of San Mateo in Silicon Valley, Ca

San Mateo, CA, November 3, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that it has received the 2000 "New
                      Product/Technology Development" Award from the Chamber of Commerce of the City of San Mateo, CA in its annual Outstanding Business
                      Awards program. SciClone is the only biopharmac...





PDF





Oct 31, 2000
New Study Helps Explain the Fundamental Role of SciClone's Zadaxin® in the Successful Treatment of Chronic Hepatitis B

San Mateo, CA, October 31, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced that a new study presented today at the 51st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Dallas further confirms ZADAXIN®'s powerful ability to activate T-cells (disease fighting white blood cells) and helps explain ...





PDF





Oct 26, 2000
SciClone Pharmaceuticals Completes North American Patent Position for ZADAXIN® in Hepatitis C

p>San Mateo, CA, October 26, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that it has received an issued patent in Canada for the use of the Company's lead drug, ZADAXIN®, for the treatment of hepatitis C, one of the world's most common blood-borne infectious diseases.  The new Canadian patent complements the Company's previo...





PDF





Oct 19, 2000
SciClone Pharmaceuticals Reports Third Quarter Results

San Mateo, CA, October 19, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN), a global specialty biopharmaceutical company, announced that it has achieved breakeven net profit status for the third quarter ended September 30, 2000, one quarter ahead of its stated goal of profitable operations by year-end.  Revenues for the third quarter o...





PDF





Sep 28, 2000
SciClone Strengthens Latin American Position for ZADAXIN in Hepatitis C

San Mateo, CA, September 28, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that it has received an issued patent in Mexico for the use of the Company's lead drug, ZADAXIN, for the treatment of hepatitis C.  SciClone also announced that Peru has expanded ZADAXIN's approval to include the treatment of hepatitis C as well as the p...





PDF





Sep 22, 2000
SciClone Pharmaceuticals Named One of Silicon Valley's 50 Fastest Growing Technology Companies

San Mateo, CA, September 22, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that it has been recognized as part of Deloitte & Touche's prestigious "Fast 50" for 2000, a ranking of the 50 fastest growing technology companies in Silicon Valley.  Rankings are based on the percentage of growth in revenues from 1995-1999.Sc...





PDF





Aug 21, 2000
SciClone Pharmaceuticals Expands Board of Directors

San Mateo, CA, August 21, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that it has appointed Jon S. Saxe, Esq. and
                      Dean S. Woodman to its Board of Directors.                      Mr. Saxe was President of Protein Design Labs, Inc. (Nasdaq: PDLI) from 1995 to early-1999, and currently serves as a Director...





PDF





Aug 7, 2000
SciClone's ZADAXIN® Receives Expanded Approval in Argentina for Hepatitis B and Hepatitis C

San Mateo, CA, August 7, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that ZADAXIN®, its lead immunotherapy, has received expanded marketing approval in Argentina for the treatment of both hepatitis B and hepatitis C.  ZADAXIN previously was approved in Argentina as a vaccine adjuvant for patients with weakened immune syst...





PDF





Aug 2, 2000
SciClone Pharmaceuticals Launches ZADAXIN® in Mexico

San Mateo, CA, August 2, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that it has begun marketing and distributing ZADAXIN®, its lead immunotherapy, in Mexico.  ZADAXIN is also approved for sale in other Latin American markets, including Argentina, Venezuela and Peru.ZADAXIN marketing and distribution in Latin Am...





PDF





Jul 31, 2000
SciClone's ZADAXIN® Prevents Formation of Lung Tumors in NIH Study

San Mateo, CA, July 31, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today the publication of results of a National Institutes of Health (NIH) preclinical study indicating that its ZADAXIN® immunotherapy may decrease formation of lung tumors.  The study, published in the peer-reviewed journal Cancer Letters (Volume 155...





PDF





Jul 17, 2000
SciClone Pharmaceuticals Announces Record Revenues for the Second Quarter of 2000

San Mateo, CA, July 17, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN), a global specialty biopharmaceutical company targeting cancer, infectious diseases and cystic fibrosis, today announced record results for the second quarter ended June 30, 2000.Revenues for the second quarter of 2000 from sales of ZADAXIN®...





PDF





Jun 6, 2000
SciClone Pharmaceuticals Granted U.S. Patent for the Use of ZADAXIN® to Treat Heptatitis B

San Mateo, CA, June 6, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the U.S. Patent and Trademark Office has
                      issued a Notice of Allowance for use of the Company's lead drug, ZADAXINÒ, for the treatment of hepatitis B. ZADAXIN is the safe, synthetic
                      preparation of thymosin alpha 1...





PDF





May 23, 2000
SciClone's ZADAXIN® Commercially Available in Italy

San Mateo, CA, May 23, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced at the UBS Warburg Global Specialty
                      Pharmaceuticals Conference that ZADAXIN, the Company's lead immunotherapy, is now commercially available in Italy. This represents the first
                      commercial launch of ZADAXIN in a Europe...





PDF





May 22, 2000
New Study Shows Improvement in Quality of Life for Chemotherapy Patients Receiving SciClone's ZADAXIN®

San Mateo, CA, May 22, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced that in a study presented today in a poster session at
                      the Annual Meeting of the American Society of Clinical Oncology (ASCO), independent investigators concluded that ZADAXIN, SciClone's lead
                      immunotherapy, can significant...





PDF





May 17, 2000
SciClone Pharmaceuticals Granted U.S. Patent for DAX, a Promising Cystic Fibrosis Drug Candidate

San Mateo, CA, May 17,2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced at the H.C. Wainwright & Co., Inc. Emerging
                      Growth Stock Conference that the U.S. Patent & Trademark Office has granted the Company an important patent concerning the use of DAX
                      (3-diallyl-8-cyclohexylxanthine) as a tr...





PDF





Apr 27, 2000
SciClone's 2000 First Quarter ZADAXIN® Sales Increase 122%

San Mateo, CA, April 27, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that first quarter 2000 sales of ZADAXIN, the Company's lead immunotherapy, were $3,499,000, an increase of 122% over first quarter 1999 ZADAXIN sales of $1,577,000. For the first quarter of 2000, the net loss of $875,000 decreased 67% when compare...





PDF





Apr 13, 2000
SciClone's ZADAXIN® Approved in South Korea

San Mateo, CA, April 13, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the approval of ZADAXIN, its lead
                      immunotherapy, in South Korea, one of the world's largest pharmaceutical markets. The South Korean approval is for use of ZADAXIN as an
                      influenza vaccine adjuvant by individuals wit...





PDF





Apr 6, 2000
ZADAXIN® Plus Chemotherapy Shows Promise for Improved Survival in Advanced Skin Cancer

San Mateo, CA, April 6, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that a study published in the peer-reviewed
                      journal Melanoma Research (Volume 10, Issue 2, April 2000) suggests that ZADAXINÒ, SciClone's lead immunotherapy, increases the
                      effectiveness of chemotherapy for metastatic...





PDF





Mar 22, 2000
FDA Grants Orphan Drug Status to Sciclone's ZADAXIN® for the Treatment of Liver Cancer

San Mateo, CA, March 22, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the U.S. Food and Drug Administration
                      (FDA) has granted Orphan Drug Status to ZADAXIN®, SciClone's lead immunotherapy, for the treatment of hepatocellular carcinoma,...





PDF





Mar 17, 2000
SciClone Receives Three New ZADAXIN® Marketing Approvals

San Mateo, CA, March 17, 2000 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that ZADAXIN, the Company's lead
                      immunotherapy, has been approved for marketing in Thailand, Laos and Malta. ZADAXIN now is approved for marketing in 19 countries,
                      principally for treatment of hepatitis B and hepatit...





PDF





Mar 13, 2000
SciClone and Sigma-Tau Sign Expanded ZADAXIN® Hepatitis C and Cancer Partnership for Europe

Rome, Italy and San Mateo, CA, March 13, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) and Sigma-Tau S.p.A., the leading
                      research-based Italian pharmaceutical company, announced today they have signed an expanded development and marketing partnership for
                      ZADAXINÒ, SciClone's host immune system enhance...





PDF





Mar 1, 2000
New Study Shows ZADAXIN's Dual Role in Immune Recognition of and Response to Cancer and Infection

San Mateo, CA, March 1, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that a study published in the peer-reviewed
                      European Journal of Immunology (March 2000, Volume 30, Issue 3) shows that ZADAXIN® (thymosin alpha 1) directly increases the immune
                      sys...





PDF





Feb 23, 2000
SciClone Awarded $300,000 Grant to Study New Immunomodulator for Tuberculosis

San Mateo, CA, February 23, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today at the 12th Annual Cruttenden Roth
                      Growth Stock Conference that it has been awarded a $300,000 grant to study SCV-07, the Company's new immunomodulator, as a potential
                      treatment for tuberculosis (TB), the most co...





PDF





Feb 15, 2000
SciClone Pharmaceuticals Moves Forward with Development of CPX for Cystic Fibrosis

San Mateo, CA, February 15, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced plans to move forward with the next stage
                      of its phase 2 development program for CPX, a novel PRT (protein repair therapy) for cystic fibrosis (CF). SciClone, working closely with
                      scientists and clinical investig...





PDF





Feb 3, 2000
SciClone Pharmaceuticals Reports 1999 Results

San Mateo, CA, February 3, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced results for the fourth quarter and year ended December 31, 1999.For the year, the Company reported total revenue of $9,397,000, a 152% increase over the $3,725,000 reported for 1998.  Sales of ZADAXINÒ, the Company's host immune system enhancer (...





PDF





Jan 27, 2000
SciClone Initiates U.S. Phase 2 Study of ZADAXIN® Plus Lamivudine for Hepatitis B

San Mateo, CA, January 27, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the start of a U.S. Phase 2 hepatitis B study
                      using ZADAXIN, the Company's host immune system enhancer (h-ISE), in combination with lamivudine, an FDA-approved nucleoside analogue.
                      The study, conducted at Loyola U...





PDF





Jan 19, 2000
SciClone Pharmaceuticals Expands Capital Base

San Mateo, CA, January 19, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the completion of a $6,100,000 private
                      placement with its largest institutional shareholder, The Brown Simpson Strategic Growth Funds. The newly acquired funds will be directed
                      toward the distribution of ZADAXIN...





PDF





Nov 19, 1999
SciClone Appoints Two New Regional Managing Directors To Expand Zaxadin® Sales In Latin America and The Middle East

San Mateo, CA, November 19, 1999 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced the appointment of Craig R. Olson as Regional Managing Director, Latin America and Kenneth R. Cowan as Regional Managing Director, Middle East for the Company's international subsidiary, SciClone Pharmaceuticals International, Ltd.  Olson and Cowan become SciClone...





PDF












































 
Email Alerts
Email Alerts
 
 
Snapshot
Snapshot
 

RSS
RSS
 
 
Print
Print
 
 
Email
Email
 

Search
Search






















 © 2017 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer. Terms of Use | Notes Regarding Forward Looking Statements 
年赛生制药公司保留所有权利。请阅读我们的免责声明。 使用条款 | 注意有关前瞻性陈述











 